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GLOSSARY 
Family History A family history of disease in an individual is the occurrence of the disease in a blood relative of that individual. 
Gene A gene is a molecular unit of heredity of a living organism. 
Genetic Counselling A service delivered by a qualified health professional that provides a comprehensive evaluation of familial risk for 
inherited disorders using kindred analysis and other methods, patient education, discussion of the benefits and harms 
of genetic testing, interpretation of results after testing (consequences and nature of the disorder, probability of 
developing or transmitting it), and discussion of management options. 
Genetic Counsellor A healthcare professional providing individuals and families with information on the nature, inheritance, and implications 
of genetic disorders to help them make informed medical and personal decisions. If it is appropriate, they will discuss 
genetic testing, coordinate any testing, interpret test results, and review all additional testing, surveillance, surgical, or 
research options that are available to members of the family. 
Genetic testing Genetic testing is a type of medical test that identifies changes in chromosomes, genes, or proteins. The results of a 
genetic test can confirm or rule out a suspected genetic condition or help determine a person’s probability of developing 
or passing on a genetic disorder. 
Germline  The cells from which eggs or sperm (i.e., gametes) are derived. 
Penetrance A characteristic of a genotype; it refers to the likelihood that a clinical condition will occur when a particular genotype is 
present. 
Proband The individual through whom a family with a genetic disorder is identified.  
Relatives – First-degree relatives These are the closest blood relatives (relatives by marriage do not count). These include father, mother, son, daughter, 
brother, sister. 
Relatives – Second-degree 
relatives 
These are blood related grandparents, grandchildren, uncles, aunts, nephews and nieces, half-brothers and half-sisters, 
on mother’s or father’s side of the family. 
Relatives – Third-degree relatives These are blood related great grandparents, great grandchildren, great uncles, great aunts, first cousins, grand-nephews 
and grand-nieces, on mother’s or father’s side of the family. 
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 SCIENTIFIC REPORT 1 INTRODUCTION 
This clinical practice guideline is based on a joint effort of the Belgian Health 
Care Knowledge Centre (KCE), the College of Human Genetics and the 
College of Oncology. This guideline is the third report in a short series of 
oncogenetic testing guidelines. 
1.1 Background 
Oncogenetic tests are tests that assist in the diagnosis of specific cancers 
that have an important hereditary component. Such tests may also assist to 
identify family members at risk of developing specific forms of cancer. This 
guideline will address the indications for genetic testing in the following 
selection of endocrine tumours / syndromes: Multiple Endocrine Neoplasia 
type 1 (MEN1), Multiple Endocrine Neoplasia type 2 (MEN2), von Hippel-
Lindau (VHL) syndrome, phaeochromcytoma and paraganglioma.  
MEN2 is a group of disorders associated with endocrine tumours (typically 
of the thyroid, parathyroid and adrenals).1 Nearly all patients develop a 
medullary thyroid carcinoma (MTC). In general, three major phenotypes are 
distinguished. MEN2A (60% of all MEN2 cases) combines MTC with 
phaeochromocytoma (10-50% of MEN2A cases) and/or primary 
hyperparathyroidism (5-20% of MEN2A cases). MEN2B (5% of all MEN2 
cases) combines MTC with phaeochromocytoma (50% of MEN2B cases) 
and typical phenotypic features such as a Marfan-type dysmorphism, 
ganglioneuromatosis and/or skeletal abnormalities. Finally, in familial MTC 
(35% of all MEN2 cases), the other components of the disease are absent. 
MEN2 is typically associated with mutations of the proto-oncogene RET. 
Epidemiological data are not available for Belgium, but the prevalence is 
estimated to be 2.5 per 100 000 in the general population.1 
MEN1 is a polyglandular genetic syndrome characterized by tumours of the 
parathyroid glands, pancreatic islet cells and/or anterior pituitary gland. 
Parathyroid tumours with primary hyperparathyroidism is the most common 
presentation (95% of all MEN1 cases). In addition to these three ‘major’ 
locations, tumours can also occur in ‘minor’ locations, such as the adrenal 
cortex. MEN1 is usually inherited (as an autosomal dominant disorder), but 
de novo mutations of the MEN1 gene (menin) are found in about 10% of 
patients. Epidemiological data are not available for Belgium, but the 
incidence has been estimated to be 0.25% from postmortem studies.2 
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The VHL syndrome is associated with a variety of benign and malignant 
tumours, in particular haemangioblastomas of the retina and central nervous 
system, endolymphatic sac tumours, phaeochromocytomas, renal cell 
carcinomas and cysts in various organs including the kidney, pancreas and 
liver.3 The VHL syndrome is inherited, and caused by germline mutations in 
the VHL tumour suppressor gene. Epidemiological data are not available for 
Belgium, but the prevalence is estimated to be 1 in 90 000 people.3 
Phaeochromocytomas are tumours arising from adrenomedullary 
chromaffin cells that commonly produce catecholamines.4 Paragangliomas 
are tumours derived from extra-adrenal chromaffin cells of the sympathetic 
paravertebral ganglia of thorax, abdomen, and pelvis, or from 
parasympathetic ganglia located along the glossopharyngeal and vagal 
nerves in the neck and at the base of the skull. In addition to the three 
syndromes described above, phaeochromocytomas and paragangliomas 
can also occur sporadically, i.e. without syndromic features. Several 
susceptibility genes have been described, with SDH mutations occurring 
most frequently. In 2011, 16 phaeochromocytomas and 9 paragangliomas 
were registered at the Belgian Cancer Registry (personal communication), 
with a European Standardized Rate of 0.14 and 0.06 per 100 000 person 
years, respectively. However, these incidences are probably 
underestimated because of underregistration. 
1.2 The need for a guideline 
At present, eight genetic centres are recognized in Belgium. However, no 
national guideline exists on the indications for genetic testing, and most 
centres follow their own protocols. Therefore, uniform criteria are needed for 
the identification and referral of patients to genetic centres for counselling, 
possibly followed by germline mutation analysis. It is important to provide 
such guidance to all clinicians active in the field. This guideline is timely 
because the new nomenclature, introduced on 1/1/2013, for genetic tests 
(article 33) and the agreement on genetic testing consultation led to 
redistribute the NIHDI budget between genetic counselling (€4,288 millions) 
and laboratory procedures (€37,795 millions). There is a need to standardise 
the use of these tests and base their use on available evidence. Early 
identification of persons at risk makes the initiation strategies possible that 
may reduce morbidity or be lifesaving, including enhanced surveillance and 
prophylactic surgery. It may also help the patient in making decisions 
concerning preconception and antenatal screening and reproduction in 
general. 
1.3 Scope 
This guideline will cover following populations: 
 Multiple Endocrine Neoplasia type 1 
 Multiple Endocrine Neoplasia type 2 
 Von-Hippel Lindau syndrome 
 Phaeochromocytoma 
 Paraganglioma 
 Relatives of patients with one of the syndromes / tumours above 
 Patients with a suspicion of one of the syndromes / tumours above 
The guideline will cover following issues: 
 Genetic testing for Succinate Dehydrogenase B, C and D (SDHB, 
SDHC, SDHD), menin, VHL and RET mutations 
The guideline will not cover following issues: 
 Genetic testing for mutations other than SDHB, SDHC, SDHD, menin, 
VHL and RET mutations 
 Clinical, biochemical and imaging follow-up of persons testing positive 
for a mutation 
 Prenatal screening for a mutation 
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1.4 Remit of the guideline 
1.4.1 Overall objectives 
This guideline provides recommendations based on current scientific 
evidence for the genetic testing of patients with the endocrine syndromes 
described above and their relatives. Clinicians are encouraged to interpret 
these recommendations in the context of the individual patient situation, 
values and preferences.  
The guidelines are based on clinical evidence and may not always be in line 
with the current criteria for NIHDI (RIZIV/INAMI) reimbursement of 
diagnostic and therapeutic interventions. The NIHDI may consider 
adaptation of reimbursement/funding criteria based on these guidelines. 
1.4.2 Target users of the guideline 
This guideline is intended to be used by care providers involved in genetic 
counseling, testing and follow-up of patients with the endocrine syndromes 
described above. It also contains recommendations for persons that must 
decide when to refer for genetic counselling and testing such as general 
practitioners, endocrinologists, oncologists, surgeons, and pathologists. It 
can also be of interest for patients and their families, hospital managers and 
policy makers. 
1.5 Statement of intent 
Clinical guidelines are designed to improve the quality of health care and 
decrease the use of unnecessary or harmful interventions. This guideline 
has been developed by clinicians and researchers for use within the Belgian 
healthcare context. It provides advice regarding the care and management 
of patients presenting with MEN1, MEN2, VHL or 
phaeochoromocytoma/paraganglioma and their relatives by care providers 
involved in genetic counseling, testing and follow-up of patients with the 
endocrine syndromes described above. 
The recommendations are not intended to indicate an exclusive course of 
action or to serve as a standard of care. Standards of care are determined 
on the basis of all the available clinical data for an individual case and are 
subject to change as scientific knowledge and technology advance and 
patterns of care evolve. Variations, which take into account individual 
circumstances, clinical judgement and patient choice, may also be 
appropriate. The information in this guideline is not a substitute for proper 
diagnosis, treatment or the provision of advice by an appropriate health 
professional. It is advised, however, that significant deviations from the 
national guideline are fully documented in the patient’s file at the time the 
relevant decision is taken. 
1.6 Funding and declaration of interest 
KCE is a federal institution funded for the largest part by INAMI/RIZIV, but 
also by the Federal Public Service of Health, Food chain Safety and 
Environment, and the Federal Public Service of Social Security. The 
development of clinical practice guidelines is part of the legal mission of the 
KCE. Although the development of guidelines is paid by KCE’s budget, the 
sole mission of the KCE is providing scientifically valid information. KCE has 
no interest in companies (commercial or non-commercial i.e. hospitals and 
universities), associations (e.g. professional associations, unions), 
individuals or organisations (e.g. lobby groups) that could be positively or 
negatively affected (financially or in any other way) by the implementation of 
these guidelines. All clinicians involved in the Guideline Development Group 
(GDG) or the peer-review process completed a declaration of interest form. 
Information on potential conflicts of interest is published in the colophon of 
this report. All members of the KCE Expert Team make yearly declarations 
of interest and further details of these are available upon request. 
  
 10  Oncogenetic testing for endocrine cancer syndromes KCE Report 242 
 
 
2 METHODOLOGY 
2.1 Introduction 
This guideline was developed using a standard methodology based on a 
systematic review of the evidence. Further details about KCE and the 
guideline development methodology are available at 
https://kce.fgov.be/content/kce-processes. 
Several steps were followed to elaborate this guideline. Firstly, clinical 
questions were developed and the inclusion and exclusion criteria were 
defined in collaboration with members of the Guideline Development Group 
(see Appendix 1). Secondly a literature review was conducted (including a 
search for recent, high-quality guidelines). Thirdly, on the basis of the results 
of the literature review, recommendations were formulated and graded 
according to the GRADE approach. 
2.2 The Guideline Development Group 
This guideline was developed as a result of a collaboration between 
multidisciplinary groups of practising clinicians and KCE experts. The 
composition of the GDG is documented in Appendix 1.  
Guideline development and literature review expertise, support, and 
facilitation were provided by the KCE Expert Team.  
The roles assigned to the GDG were:  
 To define the clinical questions, in close collaboration with the KCE 
Expert Team and stakeholders;  
 To identify critical and important outcomes; 
 To provide feedback on the selection of studies and identify further 
relevant manuscripts which may have been missed; 
 To provide feedback on the content of the guideline; 
 To provide judgement about indirectness of evidence; 
 To provide feedback on the draft recommendations; 
 To address additional concerns to be reported under a section on ‘other 
considerations’. 
2.3 Clinical research questions and definitions 
The CPG addresses the following clinical questions: 
 What is the clinical effectiveness of genetic testing in patients 
presenting with MEN1 (MEN1 mutations), MEN2 (RET mutations), VHL 
(VHL mutations) or phaeochromocytoma / paraganglioma (SDH, VHL 
and RET mutations)? 
 What is the diagnostic accuracy of clinical features for the triage for 
genetic testing of patients presenting with MEN1, MEN2, VHL or 
phaeochromocytoma / paraganglioma? 
 What is the clinical effectiveness of genetic testing of relatives of MEN1, 
RET, VHL or SDH mutation carriers? 
2.4 General approach 
To verify if high-quality, recent guidelines are available that address the 
clinical research questions, a GCP project always starts with a search for 
published guidelines. If such guidelines are available, the ADAPTE 
methodology is followed (http://www.g-i-n.net/working-groups/adaptation). 
However, we assess and summarize the underlying evidence where the 
recommendations of the guideline are based on. We only adopt the 
recommendation if the GDG agrees with the interpretation and considers the 
guideline applicable to the Belgian context. 
If no high-quality, recent guidelines are available, the general approach 
begins with the search for systematic reviews. 
For each research question, a search for systematic reviews was conducted 
in MEDLINE, Embase and The Cochrane Library (Cochrane Database of 
Systematic Reviews, DARE and HTA database). If no systematic review 
was available, a search for primary studies was performed in the same 
databases, without time restriction. Members of the GDG were also 
consulted to identify additional relevant evidence that might have been 
missed by the search. 
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2.5 Literature search and study selection 
2.5.1 Study design 
 Inclusion criteria for the study design: guidelines, systematic reviews, 
meta-analyses, RCTs, observational studies. 
 Exclusion criteria for study design: 
o Narrative review 
o Cadaver/animal studies  
o Case reports 
 Articles in Dutch, English and French were included. 
To be included, a systematic review had to: 
 address at least one of the research questions; 
 evaluate at least one of the selected outcomes; 
 search MEDLINE and at least one other electronic database; 
If more than one systematic review was identified for a particular research 
question, the focus was on the most complete systematic review. 
To be included, a primary study had to:  
 be an RCT or an observational study; 
 address at least one of the research questions; 
 evaluate at least one of the selected outcomes. 
2.5.2 Databases and date limits 
The following databases were included in the literature search:   
 The Cochrane Library (http://www.cochrane.org) 
 Medline (http://www.ncbi.nlm.nih.gov/pubmed)  
 Embase (http://www.embase.com/) 
Guidelines were identified through the search for systematic reviews and 
primary studies, and through a search of the websites of the following 
organisations: STOET (www.stoet.nl), American Thyroid Association (ATA, 
www.thyroid.org), American Association of Clinical Endocrinologists (AACE, 
www.aace.com), Endocrine Society (www.endocrine.org), and the 
European Thyroid Association (ETA, www.eurothyroid.com). Members of 
the GDG were also consulted to identify relevant evidence that might have 
been missed during the search process. 
The search for systematic reviews was limited to studies published since 
2008. The search for primary studies was not limited in time. 
2.5.3 Search strategy 
The search strategy and number of articles per database are detailed in 
Appendix 2. 
Studies were screened on title and abstract by one researcher (JV). In 
case of doubt, the content experts were consulted. In a second step, the 
remaining papers were screened by reading their full-text. If no full-text was 
available, the study was excluded for the final recommendations. Reference 
lists of the selected studies were hand searched for additional relevant 
manuscripts. Due to limited resources only articles available through the 
Vesalius Documentation and Information centre or Interlibrary Loan were 
retained. 
2.6 Quality appraisal 
Detailed results of the quality appraisal can be found in Appendix 3. 
2.6.1 Clinical practice guidelines 
The AGREE II instrument was used to critically appraise guidelines retrieved 
(JV).  
2.6.2 Systematic reviews  
Selected (systematic) reviews were critically appraised by a single KCE 
expert (JV) using the AMSTAR checklist 
(http://amstar.ca/Amstar_Checklist.php). In case of doubt, a second KCE 
expert was consulted.  
2.6.3 Primary articles 
Critical appraisal of each study was performed by a single KCE expert (JV). 
In case of doubt, a second KCE expert was consulted. 
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2.7 Data extraction  
For each included CPG the relevant recommendations were extracted. 
For each systematic review, the search date, publication year, included 
studies and main results were extracted. For RCTs and observational 
studies, the following data were extracted: publication year, study 
population, study intervention and outcomes.  
Data extraction was performed by one researcher (JV) and entered in 
evidence tables using standard KCE templates. All evidence tables are 
reported in Appendix 4. 
2.8 Statistical analyses 
Diagnostic meta-analyses were performed using the metandi or gllamm 
commands of STATA version 12.1 in case at least 4 studies were available. 
In case no meta-analysis was possible, median sensitivities and specificities 
were calculated. Medians were also calculated for the positive predictive 
value (PPV) and negative predictive value (NPV).   
2.9 Grading evidence 
Due to current methodological limitations of the GRADE system for 
diagnostic tests, GRADE was not applied to the recommendations. 
However, the GRADE tools available on www.guidelinedevelopment.org 
were used to inform the GDG about the number of false positives and 
negatives associated with clinical features when used to predict the 
presence of a mutation. Furthermore, the general philosophy of the GRADE 
system for interventions (see KCE process book, 
http://processbook.kce.fgov.be/node/51) was also used for this report (more 
specifically for the grading of the recommendations). 
For the conclusions regarding the diagnostic accuracy, pragmatic categories 
were defined: a sensitivity or specificity of at least 90% was considered high, 
80-90% was considered moderate and below 80% was considered low. The 
following considerations were made regarding diagnostic accuracy 
outcomes when evaluating the clinical features that are predictive of 
mutations: 
 True positives: would undergo genetic testing, would test positive and 
would receive screening for new manifestations; 
 False positives: would undergo genetic testing, but would test negative 
(i.e. inappropriate genetic testing); 
 True negatives: would not undergo genetic testing, would not undergo 
screening for new manifestations, and would probably never develop 
new manifestations; 
 False negatives: would not undergo genetic testing, would not undergo 
screening for new manifestations, but some would develop new 
manifestations. 
The guideline development group considered a high number of true 
negatives to be more important for the patients and their relatives than a 
high number of true positives. Furthermore, a high number of false positives 
was not considered having a high budgetary impact (because of the low 
prevalences), and avoiding a high number of false negatives was considered 
to be more important. 
2.10 Formulation of recommendations 
Based on the retrieved evidence, a first draft of recommendations was 
prepared. This first draft was, together with the evidence tables, circulated 
to the GDG two weeks prior to the face-to-face meetings (September 11, 
2014; December 5, 2014). Based on the discussion meetings a second draft 
of recommendations was prepared and once more circulated to the GDG for 
final approval (January 16, 2015).  
2.11 Final validation and external review 
As part of the standard KCE procedures, an external scientific evaluation 
(i.e. validation) of the report was conducted prior to its publication (February 
12, 2015). The current guideline was reviewed by 3 independent assessors 
(cf. names in the colophon). The validation of the report results from a 
consensus or a voting process between the validators.  
After the validation a final discussion with the GDG and stakeholders was 
organised on February 23, 2015. The recommendations prepared by the 
guideline development group were circulated to professional associations 
and patient representatives (Table 1).  
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Each association was asked to assign one or two key representatives to act 
as external reviewers of the draft guideline. All expert referees made 
declarations of interest. 
Globally, 10 external experts and/or patient representatives were involved 
in the external review of the clinical recommendations. All invited panellists 
received the scientific report for all research questions and were asked to 
indicate their level of agreement with the recommendation, with a score of 
‘1’ indicating ‘completely disagree’, ‘2’ ‘somewhat disagree’, and ‘3’ 
‘completely agree’ (the panellists were also able to answer ‘not applicable’ 
if they were not familiar with the underlying evidence). If panellists disagreed 
with the recommendation, they were asked to provide an explanation 
supported by appropriate evidence and to suggest a more appropriate 
formulation. Scientific arguments reported by these experts were used to 
adapt the formulation or the strength of the clinical recommendations. In 
Appendix 8, an overview is provided of how their comments were taken into 
account. 
Table 1 – List of professional and patient associations invited. 
 Belgian Group of Digestive Oncology 
 Belgian Group of Endoscopic Surgery 
 Belgische Vereniging voor Radiotherapie-Oncologie - Association 
Belge de Radiothérapie-Oncologie 
 Belgian Society of Medical Oncology 
 Belgian Society of Surgical Oncology 
 Kom op tegen Kanker 
 Fondation contre le cancer 
 Zelfhulpgroep NET & MEN kanker 
 VHL Family Alliance Belgium 
 
3 CLINICAL RECOMMENDATIONS 
3.1 Multiple Endocrine Neoplasia type 2 (MEN2) 
3.1.1 Evidence from indexed literature 
One recent HTA report of good quality was identified.1 The objective of the 
report was to determine whether there is sufficient evidence of clinical need, 
safety, effectiveness and cost-effectiveness to recommend the public 
funding (in Australia) of genetic testing for hereditary mutations in the RET 
gene for (1) patients with symptoms of MEN2, and (2) a family member of a 
patient with a known pathogenic RET mutation. Since the literature search 
in the MSAC 2013 report was considered to be sufficiently rigourous (up to 
August 2012), no attempt was made to identify more recent primary studies. 
For the evaluation of the safety, effectiveness and cost-effectiveness of RET 
mutation testing, MSAC proposed two management algorithms as a basis, 
one for patients presenting with a medullary thyroid carcinoma (MTC) plus 
their first degree relatives (Figure 1) and the second for patients presenting 
with phaeochromocytoma or hyperparathyroidism, and their first degree 
relatives (Figure 2).1 These pathways both include the ‘historical’ setting on 
the one hand (i.e. the investigations to be used in the absence of RET 
mutation testing), and the scenario with RET mutation testing being standard 
clinical practice on the other hand. With these two pathways in mind, MSAC 
defined PICO questions for the following four populations: 
 Patients presenting with medullary thyroid carcinoma (MTC); 
 Patients presenting with adrenal phaeochromocytoma (under 50 years 
of age); 
 Patients presenting with hyperparathyroidism plus a diagnosis of MTC 
or phaeochromocytoma in a close relative; 
 First-degree relatives of patients with a diagnosis of MEN2 or a known 
pathogenic RET mutation. 
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For all four populations a pathway including RET mutation testing (and 
targeted interventions depending on the outcome of RET mutation testing) 
was compared with the ‘historical’ setting, using long-term clinical 
assessment (ideally over the life-time of the patient) as the reference 
standard.  
However, this reference standard is imperfect, since persons with a 
pathological RET mutation associated with MEN2 prior to the development 
of MTC would ideally undergo a prophylactic thyroidectomy, making it 
impossible to determine whether the individual actually would have 
developed an MTC or not.1 
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Figure 1 – Management algorithm for use of a RET mutation test to diagnose and predict MEN2 (MTC identified in index case prior to genetic testing).1 
 
a Biochemical screening and imaging for further features of MEN2: plasma or urine catecholamine (and adrenal imaging e.g. adrenal CT scan or MRI and/or MIBG scan if these are elevated) to 
assess for phaeochromocytoma, serum calcium (and parathyroid hormone if elevated) to assess for hyperparathyroidism; bSurveillance in those who have had a total thyroidectomy: Annual general 
clinical examination, examination of thyroid (or thyroid bed if post-thyroidectomy), biochemical screen for phaeochromocytoma, screen for hyperparathyroidism (total and ionised serum Ca2+) and 
calcitonin and carcinoembryonic antigen to detect persistence or recurrence of MTC; cHistorical surveillance in those at risk of MEN2 who have not had a total thyroidectomy: Annual general clinical 
examination, examination of thyroid (or thyroid bed if post-thyroidectomy), biochemical screen for phaeochromocytoma, screen for hyperparathyroidism (total and ionised serum Ca2+); pentagastrin-
stimulated serum calcitonin and neck ultrasound to assess for a medullary thyroid carcinoma; d2nd degree relatives would only be considered to be at genetic risk if 1st degree relatives have a RET 
mutation, clinical features of MEN2, or if information regarding 1st degree relatives is unavailable  
Historical pathway 
 (all patients considered 
potentially to have MEN2) 
Treatment of medullary thyroid carcinoma (total 
thyroidectomy) and any other MEN2 features detected 
Biochemical screening and imaginga for 
further features of MEN2  
Lifelong thyroxine and surveillanceb, early detection of 
MEN2 features, treatment as required  
Treatment of medullary thyroid carcinoma 
(total thyroidectomy), lifelong thyroxine, 
and monitoring for recurrence or 
persistence of medullary thyroid carcinoma 
Genetic counselling, biochemical screening and imaginga to 
identify MEN2 features b in 1st and 2nd degree relatives, at 
genetic riskd, and treatment of any clinical features identified 
Lifelong surveillanceb, early detection of MEN2 features, 
treatment as required (total thyroidectomy once calcitonin 
levels rise, or on basis of biopsy of thyroid nodule detected 
clinically or on ultrasound) 
Biochemical screening and imaginga 
for further features of MEN2  
Patients presenting with clinical features of MEN2 including a medullary thyroid carcinoma (any age) 
Current pathway Historical pathway 
+ve for RET 
mutation  
Genetic counselling and 
genetic testing of RET gene  
Relatives do not require testing for 
specific RET mutations or monitoring for 
MEN2 
No further follow-up 
+ve  
  -ve 
Biochemical screening and imaginga to identify MEN2 
features + prophylactic thyroidectomy, and treatment of any 
other clinical features identified 
Lifelong thyroxine and surveillanceb, early detection of MEN2 
features, treatment as required 
Genetic counselling and genetic testing in 1st and 2nd 
degree relatives, at genetic riskd, for specific RET 
mutation 
-ve for RET mutation  
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Figure 2 – Management algorithm for use of a RET mutation test to diagnose and predict MEN2 (no MTC identified in index case prior to genetic 
testing).1 
 
a Screening for other hereditary disorders: genetic testing of the VHL gene for von Hippel Lindau disease, genetic testing for SDHB, SDHC and SDHD mutations; if serum calcium and parathyroid 
hormone are elevated then additional testing for features of MEN1 (serum gastrin, serum insulin, serum glucagon, serum pancreatic polypeptide, serum vasoactive intestinal peptide, serum prolactin, 
growth hormone, and adrenocorticotrophic hormone (ACTH)); bHistorical biochemical screening and imaging for further features of MEN2: pentagastrin-stimulated serum calcitonin and neck 
ultrasound to assess for a medullary thyroid carcinoma; plasma or urine catecholamine (and adrenal imaging e.g. adrenal CT scan or MRI and/or MIBG scan if these are elevated) to assess for 
phaeochromocytoma if not the presenting clinical feature, or serum calcium (and parathyroid hormone if elevated) to assess for hyperparathyroidism if not the presenting clinical feature; cCurrent 
biochemical screening and imaging for further features of MEN2:  plasma or urine catecholamine (and adrenal imaging e.g. adrenal CT scan or MRI and/or MIBG scan if these are elevated) to 
assess for phaeochromocytoma if not the presenting clinical features, or serum calcium (and parathyroid hormone if elevated) to assess for hyperparathyroidism if not the presenting feature; 
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dHistorical surveillance: Annual general clinical examination, examination of thyroid (or thyroid bed if post-thyroidectomy), biochemical screen for phaeochromocytoma, screen for 
hyperparathyroidism (total and ionised serum Ca2+); plus pentagastrin-stimulated serum calcitonin and neck ultrasound to assess for a medullary thyroid carcinoma  or  calcitonin and 
carcinoembryonic antigen after surgery for medullary thyroid carcinoma; Current surveillance: Annual general clinical examination, examination of thyroid (or thyroid bed if post-thyroidectomy), 
biochemical screen for phaeochromocytoma, screen for hyperparathyroidism (total and ionised serum Ca2+) ±  calcitonin and carcinoembryonic antigen after surgery for MTC 
3.1.1.1 Effectiveness 
MSAC identified nine historical controlled studies (eight at high risk of bias, 
one at moderate risk of bias because of very good reporting) that provided 
direct evidence showing that health outcomes are likely to be better for 
patients diagnosed with the addition of RET mutation testing:1 
 One historical controlled study reported on the rate of death following 
RET mutation testing and subsequent treatments. Of those patients 
diagnosed and treated without knowledge of their RET mutation status, 
31% died from distant metastases, compared with no patients 
diagnosed since the use of RET mutation testing. However, because of 
the lack of details in the article and the high risk of bias inherent in the 
study design (different length of follow-up in the two study arms), no 
strong conclusions were drawn by MSAC. 
 Six historical controlled studies reported on the percentage of patients 
who were free of disease or who had residual or recurrent disease 
following total thyroidectomy. The six studies were consistent in the 
direction of effect, indicating that fewer patients who had been 
diagnosed with RET mutation testing subsequently had residual 
disease, recurrent disease or died, compared with those who were 
diagnosed without knowledge of RET mutations (RR=0.28, 95%CI 0.17 
to 0.45). Again, these results are probably biased because of the 
different length of follow-up in the two study arms. 
 Seven historical controlled studies reported on the incidence and 
severity of MTC in patients who underwent total thyroidectomy in the 
era prior to RET mutation testing compared with the era subsequent to 
the introduction of RET mutation testing. Those diagnosed and treated 
since RET mutation testing became available had almost half the risk 
of having an MTC at the time of surgery, compared with those whose 
treatment decisions were based on biochemical screening in the pre-
RET mutation testing era (RR=0.53, 95%CI 0.32 to 0.90). It is unknown 
whether any clinical benefit has occurred in index patients, or whether 
all the benefits found have been due to more effective management of 
family members. 
 One historical controlled study reported that age at diagnosis reduced 
for patients with MEN2A and FMTC between two surveys in Japan, one 
performed in 1996 (capturing data prior to the availability of RET 
mutation testing) and the other in 2002. Age at diagnosis in patients with 
MEN2B increased marginally, likely just through chance given the small 
sample. However, the MEN2B phenotype is more clearly diagnosed 
than the MEN2A, so genetic testing has probably had less impact on 
patients and their family members with or suspected of having MEN2B 
than MEN2A.  
 Five historical controlled studies reported that the introduction of RET 
mutation testing allowed the age to significantly reduce at the time of 
total thyroidectomy. One Australian study reported that the mean age 
decreased from 32 years to 16 years. 
Assessment of indirect (diagnostic accuracy) evidence supported the 
conclusions based on direct evidence of the impact of testing on patient 
health outcomes.1 One historical controlled study and 3 case series reported 
instances of false positive results based on calcitonin levels, which led to 
patients either undergoing total thyroidectomy or being scheduled for 
surgery that was subsequently cancelled after a negative RET mutation 
status was identified. One single case of an individual free from RET 
mutations, in a family with known mutations, who had an MTC was noted. It 
is unknown whether this could be considered a false negative RET mutation 
test or a coincidental finding of a spontaneous MTC in a RET-mutation-
negative family member of an FMTC kindred. Although a true comparison of 
accuracy was not able to be performed given the lack of long-term clinical 
follow-up data to use as a reference standard for MEN2 diagnosis, the 
limited evidence available would suggest that diagnoses made with the 
addition of RET mutation testing are likely to be more accurate than those 
made on the basis of biochemical screening. As the treatment option 
(thyroidectomy) is the same, irrespective of early or late identification of 
MEN2, and has proven effectiveness, it is unlikely that studies assessing the 
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comparative effectiveness of thyroidectomy in an ‘earlier (RET-mutation-
tested)’ versus ‘later (non-RET-mutation-tested)’ MEN2 diagnosed 
population are necessary or will be conducted. 
Patients who are asymptomatic gene carriers are likely to undergo 
prophylactic total thyroidectomy on the basis of this knowledge. Prophylactic 
surgery is associated with having a lower stage of MTC disease at time of 
surgery, compared with surgery performed on the basis of calcitonin levels. 
3.1.1.2 Safety 
MSAC did not identify studies that mentioned any safety concerns regarding 
RET mutation testing or surveillance for features of MEN2.1 One historical 
controlled study reported one death from surgical complications in the pre-
RET mutation testing era, compared with one death from surgical 
complications after diagnosis by RET mutation testing, with similar numbers 
of patients treated in both scenarios (N=29 in pre-RET mutation testing era; 
N=31 in RET mutation testing era). No further details on the nature of these 
deaths or information on confounding factors were reported. 
Twelve case series reported on rates of adverse events due to total 
thyroidectomy, performed after RET mutation testing identified the patients 
as having (N=2), or being at risk of having (N=10), MEN2.1 Transient 
hypoparathyroidism was the most commonly reported adverse event, 
mentioned in 8 studies, with rates between 5.0% and 36.4%. Permanent 
hypoparathyroidism, mentioned in 4 studies, occurred in 5.9-13.6% of 
patients. Temporary laryngeal nerve palsy occurred in 4.5-5.9% of patients, 
and one case of permanent laryngeal nerve palsy was reported (1.3% in 1 
study). 
Other complications following total thyroidectomy were one case of arterial 
bleeding requiring re-operation, one case of permanent unilateral Horner’s 
syndrome, and one paediatric case with fluctuating thyroid function test 
results despite good thyroxine replacement compliance at 1-year follow-up.1 
3.1.1.3 Cost-effectiveness 
MSAC conducted an economic evaluation for both (1) RET mutation testing 
in potential index cases – MTC or phaeochromocytoma under 50 years of 
age – and (2) RET mutation testing in index cases and additional familial 
genetic testing in first- or second-degree relatives of identified RET-
mutation-positive index cases.1 With respect to the economic evaluation of 
genetic testing in potential index cases alone, a cost analysis (cost-
minimisation) approach was used, as there is no evidence to suggest that 
health outcomes within the index case will be affected by genetic testing. On 
the contrary, with respect to familial testing, a cost-utility analysis was 
undertaken, as the ability to identify RET-mutation-positive family members 
via testing allows for prophylactic thyroidectomy treatment and therefore 
both health costs and outcomes are affected. 
The cost-minimisation analysis of genetic testing in potential index cases 
demonstrated that cost savings occur within 5 years of testing.1 Over the 
course of 30 years, savings of approximately $535 per MTC patient tested, 
or $1 458 per phaeochromocytoma patient under 50 years of age tested, 
would be expected compared with a scenario where testing was not 
available. 
With respect to the cost-utility analysis of genetic testing of potential index 
cases and family members of patients identified as RET-mutation-positive, 
the results indicated that availability of genetic testing ‘dominates’ (i.e. it 
results in both improved health outcomes and cost savings), compared with 
the alternative scenario where testing is not available. 
Sensitivity analyses suggested that the base-case economic conclusions 
are relatively robust. 
Based on these findings MSAC concluded with reasonable certainty that 
RET mutation testing and subsequent targeted surveillance (in comparison 
with broader and increased reliance on imaging/biochemical surveillance) is 
cost-effective.1 
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3.1.2 Overview of published guidelines 
Two consensus-based guidelines contain recommendations about RET 
mutation testing in patients with the MEN2 syndrome or their relatives.5, 6 
Both guidelines lack a good description of their methodology, although the 
ATA 2009 guideline was based on a Medline search. None of the guidelines 
contains detailed quality appraisal results of the included studies or evidence 
tables. 
Both guidelines recommend RET mutation testing for patients with MTC or 
MEN2 (Table 2). Furthermore, both guidelines also recommend RET 
mutation testing in first-degree relatives of known mutation carriers before 5 
years of age (exact age depending on the type of RET mutation). 
In addition, the ATA 2009 guideline contains some more specific 
recommendations about RET mutation in patients with intestinal 
ganglioneuromatosis, lichen planus amyloidosis or pruritis in the central 
upper back. 
Table 2 – Overview of published guidelines on RET mutation testing for the MEN2 syndrome. 
Guideline Recommendation AGREE II score ‘Methodology’ 
ATA 2009 All patients with a personal medical history of primary C cell hyperplasia, MTC, or MEN2 should be 
offered germline RET testing 
25.0% 
 The differential diagnosis in patients with intestinal ganglioneuromatosis should include MEN2B, which 
together with their history and physical examinations, family history, and ganglioneuromatosis 
histology may prompt germline RET testing 
 
 All people with a family history consistent with MEN2 or FMTC, and at risk for autosomal dominant 
inheritance of the syndrome, should be offered RET testing. For MEN2B this should be done shortly 
after birth. For MEN2A and FMTC this should be done before 5 years of age 
 
 Lichen planus amyloidosis or pruritis in the central upper back may indicate the presence of a 634 
codon mutation and should prompt genetic testing 
 
 Pre- and post-test genetics counseling by a genetics counselor, or other qualified professional, should 
be offered to all patients undergoing RET testing 
 
 Once a germline RET mutation has been identified in a family, RET mutation analysis should be offered 
to all first-degree relatives of known mutation carriers which should be done before the age of 
recommended prophylactic thyroidectomy whenever possible 
 
STOET 2010 RET mutation analysis in 
- Patients with MEN2 syndrome; 
- Patients with sporadic MTC; 
- Patients with sporadic pheochromocytoma aged < 50 years 
6.3% 
 In case of known RET mutation: RET mutation analysis in first-degree relatives at young age (0-5 
years) 
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Conclusions 
Overall, clinical management with the addition of RET mutation testing would appear to have superior effectiveness and at least non-inferior safety, compared 
with diagnosis and treatment of MEN2 without knowledge of RET mutation status. 
Other considerations 
Factor Comment 
Balance between clinical 
benefits and harms 
Clinical management with the addition of RET mutation testing would appear to have superior effectiveness and at least 
non-inferior safety, compared with diagnosis and treatment of MEN2 without knowledge of RET mutation status 
Quality of evidence The direct evidence is limited to observational studies (historical controlled studies) 
Costs (resource allocation)  RET mutation testing is billed using the nomenclature code 565515 – 565526 (€353.30 anno 2014). 
 Several recognized Belgian genetic centres provide RET mutation testing. 
 MSAC concluded with reasonable certainty that RET mutation testing and subsequent targeted surveillance (in 
comparison with broader and increased reliance on imaging/biochemical surveillance) is cost-effective in an 
Australian context. 
Patients values and preferences According to the patient representatives, patients with MEN2 and their relatives should be clearly informed about the 
risk for medullary thyroid carcinoma and other typical manifestations. They should also be informed about the necessary 
surveillance for new manifestations, therapeutic options (including prophylactic thyroidectomy) and fertility planning (if 
applicable). Psychosocial support should also be offered. 
Comments  In some cases, more specifically RET mutations with a low penetrance (ATA risk level A)5, RET mutation analysis 
of first-degree relatives can be postponed until after the age of 5 years. These relatives can be followed-up clinically 
(calcitonin and neck ultrasonography) and treated with total thyroidectomy in case of abnormal findings. 
 Treatment (including surgery) should not be delayed because of genetic testing.  
 
Recommendations Strength of 
Recommendation 
 Pre- and post-test genetic counselling should be offered to all patients with a clinical diagnosis of MEN2 (see box) or a sporadic 
MTC. 
Strong 
 All patients with a clinical diagnosis of MEN2 (see box) or a sporadic MTC, and selected patients with a phaeochromocytoma * 
should be offered germline RET testing. 
Strong 
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Recommendations Strength of 
Recommendation 
 Once a germline RET mutation has been identified in a proband, RET mutation analysis should be offered to all first-degree 
relatives#, preferably before the age of 5 years. 
Strong 
* See chapter 1.1. 
# Or first-degree relatives of patients with clinical MEN2 who died before genetic testing was carried out. 
 
Criteria for clinical diagnosis of MEN2 
 MEN2A: individual with (1) MTC and at least one family member with primary hyperparathyroidism and/or phaeochromocytoma, or (2) with at least two of 
the three major manifestations (MTC, phaeochromocytoma, primary hyperparathyroidism) 
 MEN2B: individual with MTC, phaeochromocytoma and other characteristic features (i.e. mucosal ganglioneuromas, gastrointestinal ganglioneuromas, eye 
abnormalities including corneal nerve thickening, and/or skeletal abnormalities including marfanoid body habitus) 
 Familial MTC: family with at least 4 members diagnosed with MTC (in the absence of pheochromocytoma or parathyroid adenoma/hyperplasia) 
 
3.2 Multiple Endocrine Neoplasia type 1 (MEN1) 
3.2.1 Evidence from indexed literature 
3.2.1.1 Diagnostic accuracy of individual clinical and tumour 
characteristics for the detection of mutations 
Eight studies contained sufficient information to calculate the diagnostic 
accuracy of several clinical features for the detection of MEN1 mutation in 
patients with MEN1 phenotype or MEN1-related state (Table 3).7-14 None of 
these clinical features appeared to have a good diagnostic accuracy. Having 
a parathyroid tumour was found to be the most sensitive clinical feature both 
for patients with the MEN1 phenotype (pooled sensitivity 99%, 95%CI 93-
100%) as for patients with a MEN1-related state (1 small study, sensitivity 
100%). However, with an estimated pre-test probability of 47% and on 1 000 
evaluated patients, 392 patients with a parathyroid tumour would wrongly be 
predicted as having a MEN1 mutation.
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Table 3 – Diagnostic accuracy of clinical features for the detection of MEN1 mutation in patients with MEN1 phenotype or MEN1-related state. * 
 
* Italic = medians, bold = pooled. $ Medians from unselected populations. 
3.2.1.2 Published models and proposed screening algorithms 
No models were found for MEN1 mutation testing in patients with clinical 
MEN1. However, de Laat et al. published a model predicting the risk of 
having a MEN1 mutation in patients with sporadically occurring endocrine 
tumours.15 From 1 185 MEN1 mutation analyses performed between 1998 
and 2010, 365 patients were retrospectively included. Patients with clinical 
MEN1, a known MEN1 family member, missing clinical information or 
erroneuous indication for ordering a MEN1 mutation analysis were excluded. 
The following variables were considered candidate predictors for a MEN1 
mutation: patients’ age at the moment of DNA testing, recurrent or 
multiglandular disease primary hyperparathyroidism, non-recurrent primary 
hyperparathyroidism, neuroendocrine tumours of the pancreas and 
duodenum, pituitary tumours, neuroendocrine tumours of stomach, lung, or 
thymus, adrenal hyperplasia or adenomas, and a family history of endocrine 
tumors. Based on a multivariate analysis, the following predictors were 
retained in the model: recurrent or multiglandular disease primary 
hyperparathyroidism (OR 162.4, 95%CI 30.36 to 868.55), non-recurrent 
primary hyperparathyroidism (OR 25.78, 95%CI 8.10 to 82.12), 
neuroendocrine tumours of the pancreas and duodenum (OR 17.94, 95%CI 
5.86 to 54.87), pituitary tumours (OR 4.71, 95%CI 1.86 to 11.97), 
neuroendocrine tumours of stomach, lung, or thymus (OR 25.84, 95%CI 
4.40 to 151.80), family history of MEN1-related endocrine tumors (OR 4.53, 
95%CI 1.93 to 10.61), and age (OR 0.96, 95%CI 0.94 to 0.98). The 
diagnostic accuracy of the model was good, with an area under the curve 
(c-statistic) of 0.86 (95%CI 0.81-0.90). The model was externally validated 
in a Swedish cohort of 144 patients with sporadically occurring endocrine 
tumours. The c-statistic in this cohort was 0.77 (95%CI 0.66-0.88). 
Based on the validated model, a nomogram was constructed (Figure 3). 
Appendix 6.2 provides some guidance on how to use the nomogram. 
A limitation of the study is that the included patients underwent MEN1 
mutation testing because the referring physician suspected the MEN1 
syndrome, without having uniform referral criteria (>30% did not meet the 
Dutch 2001 testing criteria). This can have created a selection bias. 
 
Median Median Median
Population Clinical feature N studies N patients  prevalence Sensitivity * Specificity *  PPV NPV Prevalence $ False negatives False positives
MEN1 phenotype Familial 4 191 61% 71% 87% 97% 64% 47% 137 69
Three major lesions 5 382 47% 31% 96% 79% 62% 47% 324 21
Parathyroid tumour 4 298 44% 99% 26% 49% 99% 47% 5 392
Pituitary tumour 4 298 44% 53% 35% 42% 45% 47% 221 344
Pancreatic tumour 3 146 47% 82% 67% 64% 82% 47% 85 175
Minor lesions 2 126 47% 20% 87% 63% 55% 47% 376 69
MEN1-related state Familial 4 532 29% 76% 76% 54% 89% 8% 19 221
Parathyroid tumour 1 13 8% 100% 42% 13% 100% 8% 0 534
Pituitary tumour 1 13 8% 0% 75% 0% 90% 8% 80 230
Pancreatic tumour 1 13 8% 0% 83% 0% 91% 8% 80 156
Minor lesions 1 13 8% 0% 25% 0% 75% 8% 80 690
Results per 1 000 patients evaluated
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Figure 3 – Nomogram to predict MEN1 mutation in patients with sporadically occurring endocrine tumours, proposed by de Laat et al.15 
 
NET: neuro-endocrine tumours; pHPT: primary hyperparathyroidism; PIT: pituitary tumour.  
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3.2.1.3 Genetic screening of relatives 
Six studies provided information on the use of MEN1 screening of relatives. 
Balogh et al. tested 21 first-degree relatives.7 All of the six symptomatic 
relatives tested positive, while one out of fifteen (7%) asymptomatic relatives 
tested positive. Lairmore et al. tested 56 at-risk relatives from 9 unrelated 
MEN1 kindreds.16 Seven patients (13%) tested positive. Hypercalcemia was 
either present at the time of genetic diagnosis or developed during the period 
of follow-up in 6 patients. One patient has not yet developed 
hyperparathyroidism after a mean follow-up 35.8 months. Lourenco et al. 
included 141 at-risk relatives from 13 unrelated index cases.17 Thirty-nine 
relatives (28%) tested positive for a MEN1 mutation. Of these, 28 were 
symptomatic and detected through clinical screening. Eleven patients were 
asymptomatic. Of the 102 relatives without a MEN1 mutation, one had a 
sporadic primary hyperparathyroidism (MEN1 phenocopy). Tham et al. 
tested 169 relatives, and found a MEN1 mutation prevalence of 18% in the 
presymptomatic relatives and 94% in the symptomatic relatives.13Tso et al. 
found a prevalence of 19% of MEN1 mutations in 47 relatives.14 The nine 
mutation carriers were all clinically affected. Finally, Waterlot et al. included 
91 members from a MEN1 family.18 Of these, 54 were clinically screened in 
the period 1992-1995, and 14 were found to be affected. From 1995 
onwards, genetic screening was performed. All 14 clinically affected family 
members tested positive for a MEN1 mutation. Thirty-four asymptomatic 
family members were also genetically screened, and six were found to be 
positive. The 28 mutation-negative family members were excluded from 
annual clinical screening, while ten of these were annually screened before 
their mutation-status was known. 
Two studies reported on the age-related penetrance of MEN1. Bassett et al. 
calculated the age-related penetrance in 320 members of 43 unrelated 
probands.19 Two-hundred and one MEN1 mutant-gene carriers were 
identified, of which 155 were clinically affected. The age-related penetrance 
was 0% at <5y, 52% at 20y and 100% at 60y. Schaaf et al. analyzed data of 
419 individuals, including 306 MEN1 patients.20 The age-related penetrance 
was 10%, 35%, 67%, 81% and 100% at 20, 30, 40, 50 and 65y, respectively. 
3.2.1.4 Impact of genetic screening on outcomes 
One retrospective study compared the outcomes of clinically versus 
genetically detected cases. Pieterman et al. included 74 patients with a 
clinical or genetic diagnosis of MEN1.21 More patients with a clinical 
diagnosis had three manifestations at the time of MEN1 diagnosis (3 vs. 0) 
or at the end of follow-up (6 vs. 4). Furthermore, more patients with a clinical 
diagnosis had metastases (10 vs. 0) or died during follow-up (10 vs. 0). Five 
of these deaths were MEN1-related. However, the sample was not 
consecutive: 22 patients with an uncertain diagnosis of MEN1 and 4 patients 
with insufficient information were excluded. Also, the median follow-up was 
longer in the group with a clinical diagnosis (11y vs. 3y). 
3.2.2 Overview of published guidelines 
One consensus-based guideline contains recommendations about mutation 
testing in patients with the MEN1 syndrome or their relatives.6 This guideline 
lacks a good description of its methodology. Furthermore, the guideline does 
not contain detailed quality appraisal results of the included studies or 
evidence tables. The recommendations are presented in Table 4. According 
to the STOET 2010 guideline a clinical diagnosis of MEN1 is made when 3/5 
typical MEN1 tumours are present (parathyroid tumours, neuroendocrine 
tumours of pancreas/duodenum, anterior pituitary tumours, adrenocortical 
tumours and neuroendocrine tumours of the stomach, lungs or thymus) or 
when 1/5 typical MEN1 tumour is present in combination with a first-degree 
family member with MEN1. 
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Table 4 – Overview of published guidelines on mutation testing for the MEN1 syndrome. 
Guideline Recommendation AGREE II score ‘Methodology’ 
STOET 2010 MEN1 mutation analysis in 
 Patients with clinical MEN1 syndrome; 
 First-degree relatives of MEN1 mutation carriers; 
 First-degree relatives of patients with clinical MEN1 syndrome; 
 Suspicion of MEN1 syndrome: 
o 1/5 MEN1 tumours and <35y 
o Multiple MEN1 tumours in one organ 
o 2/5 MEN1 tumours 
6,3% 
 In case of known MEN1 mutation: mutation analysis in first-degree relatives starting from 5y  
Conclusions 
 No validated models / algorithms exist for genetic testing of patients with clinical MEN1 syndrome. One validated model exists for MEN1 mutation testing in 
patients with sporadically occurring endocrine tumours.   
 No single clinical feature has a good diagnostic accuracy to guide mutation testing. 
 Genetic screening of relatives can preclude mutation-negative relatives from annual clinical screening. 
 Evidence from one study of very low quality suggests that genetic screening for MEN1 mutations is associated with better outcomes than clinical screening. 
Other considerations 
Factor Comment 
Balance between clinical 
benefits and harms 
No evidence was found on harms associated with genetic testing. Only one study of very low quality suggests that 
genetic screening for MEN1 mutations is associated with better outcomes than clinical screening. The expected benefits 
of MEN1 genetic testing in patients with a clinical diagnosis or suspicion of MEN1 are (1) a confirmation of the diagnosis 
as such, (2) the identification of the need for targeted surveillance for MEN1-associated tumours, and (3) the 
identification of the need of first-degree relatives to undergo genetic counselling and testing.  
Genetic screening of relatives can preclude mutation-negative relatives from annual clinical screening. Mutation-positive 
relatives will enter surveillance programmes targeted at early diagnosis of MEN1-associated tumours. 
Quality of evidence Direct evidence is based on one study of very low quality. No validated algorithms are available. 
Costs (resource allocation)  MEN1 mutation testing is billed using the nomenclature code 565515 – 565526 (€353.30 anno 2014). 
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Factor Comment 
 Several Belgian genetic centres provide MEN1 mutation testing. 
Patients values and preferences According to the patient representatives, patients with MEN1 and their relatives should be clearly informed about the 
risk for typical manifestations. They should also be informed about the necessary surveillance for new manifestations, 
therapeutic options and fertility planning (if applicable). Psychosocial support should also be offered. 
Comments Treatment (including surgery) should not be delayed because of genetic testing.  
 
Recommendations Strength of 
Recommendation 
 Pre- and post-test genetic counselling should be offered to all patients with a clinical diagnosis or suspicion of MEN1 (see box). Strong 
 All patients with a clinical diagnosis of MEN1 (see box) should be offered MEN1 genetic testing. Strong 
 In patients with a clinical suspicion of MEN1 (see box) MEN1 genetic testing may be considered. Weak 
 MEN1 mutation analysis should be offered to all first-degree relatives of MEN1 mutation carriers*. Strong 
* Or first-degree relatives of patients with clinical MEN1 who died before genetic testing was carried out. 
Criteria for clinical diagnosis of MEN1 
 
 At least two of the three major MEN1-associated tumours (parathyroid tumours, neuroendocrine tumours of pancreas/duodenum, anterior pituitary tumours). 
 One of the three major MEN1-associated tumours in a first-degree relative of a case with a clinical diagnosis of MEN1. 
Criteria for clinical suspicion of MEN1 
 One of the three major MEN1-associated tumours in combination with one minor MEN1-associated tumour (adrenocortical tumours or neuroendocrine 
tumours of the stomach, lungs or thymus). 
 Multiple MEN1-associated tumours in one organ. 
 One MEN1-associated tumour at an age < 35 years and a family member with a different MEN1-associated tumour. 
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3.3 von Hippel-Lindau (VHL) syndrome 
3.3.1 Evidence from indexed literature 
One recent HTA report of good quality was identified.3 The objective of the 
report was to determine whether there is sufficient evidence in relation to 
clinical need, safety, effectiveness and cost-effectiveness to recommend 
public funding for genetic testing for hereditary mutations in the VHL gene 
for (1) patients with symptoms of VHL syndrome and (2) a family member of 
a patient with a known VHL mutation. Since the literature search in the 
MSAC 2011 report was considered to be sufficiently rigourous (up to May 
2011), no attempt was made to identify more recent primary studies.  
For the evaluation of the safety, effectiveness and cost-effectiveness of VHL 
mutation testing, MSAC proposed a management algorithm as a basis 
(Figure 4).3 This pathway includes the ‘historical’ setting on the one hand 
(i.e. the investigations to be used in the absence of VHL mutation testing), 
and the scenario with VHL mutation testing being standard clinical practice 
on the other hand. With this pathway in mind, MSAC defined PICO questions 
for the following two populations: 
 Patients presenting with one or more clinical features suggestive of VHL 
syndrome; 
 Clinically unaffected first- or second-degree family members of patients 
with clinically diagnosed VHL syndrome and/or a diagnosed VHL 
genetic abnormality. 
For both populations a pathway including VHL mutation testing (and 
targeted interventions depending on the outcome of VHL mutation testing) 
was compared with the ‘historical’ setting, using long-term clinical 
assessment (ideally over the life-time of the patient) as the reference 
standard.3 
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Figure 4 – Management algorithm for use of VHL genetic testing in patients who present with clinical features suggestive of VHL syndrome, as well 
as their first- and second-degree relatives.3 
 
1st degree relatives are parents, offspring and siblings that share 50% of their genes; 2nd degree relatives are grandparents, grandchildren, uncle, auntie, nephew, niece, half-sibling that share 25% of 
their genes; a Surgical resection, radiotherapy, laser therapy, anti-VEGF therapy; bClinical testing = CT, MRI, ultrasound, urine and blood tests, family history, clinical history, other tests as 
appropriate to identify any signs of disease other than presenting complaint; biopsy and histopathology of any neoplasms; cScreening = CT, MRI, ultrasound, urine and blood tests; CNS=central 
nervous system 
 
Early detection of neoplasms, treatment as required, and 
continued screeningb 
+ve for 
syndrome 
AND -ve for 
mutation 
(somatic 
mosaicism) 
+ve OR -ve for 
syndrome AND 
+ve for mutation 
Continued monitoring of 
incident neoplasm/ no further 
follow-up 
Proposed pathway Current pathway 
+ve 
 
-ve for syndrome AND 
mutation 
1st or 2nd degree relatives do 
not require testing for VHL 
mutations or monitoring for 
VHL syndrome 
1st or 2nd degree relatives do not 
require monitoring for VHL 
syndrome 
Treatment of any other neoplasms detecteda and / or 
continued monitoring of incident neoplasm 
+ve  
-ve 
 
1st and 2nd degree relatives receive clinical testing and 
routine lifelong screening to identify neoplasmsb 
1st and 2nd degree relatives receive clinical testing and 
routine lifelong screening to identify neoplasmsb 
Clinical testing for VHL syndromeb plus genetic 
counselling and testing for VHL mutation 
Early detection of neoplasms, treatment as required, and 
continued screeningb 
Early detection of neoplasms, treatment as required, and 
continued screeningb 
Treatment of presenting complainta or monitoring of incident neoplasm 
Routine lifelong screening to identify new neoplasmsb 
Continued monitoring of 
incident neoplasm/ no further 
follow-up 
 
Clinical testing for VHL syndromeb 
-ve No further 
follow-up 
Genetic counselling and testing 
in 1st and 2nd degree relatives 
for familial VHL mutation 
Patients presenting with one or more clinical features suggestive of VHL syndrome: 
Haemangioblastomas of the retina or CNS, or phaeochromocytomas 
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3.3.1.1 Effectiveness 
Index cases 
No direct evidence was identified by MSAC comparing patient health 
outcomes following genetic testing in addition to usual clinical diagnosis 
versus usual clinical diagnosis alone in patients suspected of having VHL 
syndrome, or for assessing the effectiveness of VHL genetic testing when 
used as a triage test for life-long screening of family members.3 Given that 
health benefits are derived from reduced morbidity and mortality due to 
annual screening for early detection of newly developed neoplasms, and 
that the annual screening protocol is identical for all patients clinically 
diagnosed with VHL syndrome, irrespective of their VHL mutation status, the 
lack of comparative data was predictable. It is therefore unclear what impact, 
if any, the addition of VHL genetic testing to clinical diagnosis has on the 
health outcomes of patients suspected of VHL syndrome. 
 
 
 
 
 
According to MSAC, the VHL genetic testing methods of direct DNA 
sequencing of PCR products from all three exons of the VHL gene, plus a 
method to detect large deletions of the VHL gene such as MLPA, appeared 
to be the most accurate of the modalities available (Table 5).3 This dual 
testing methodology is highly accurate, with median 100% sensitivity, 
specificity, positive predictive and negative predictive values. However, 
despite this accuracy, a false negative rate of 10.2% and a false positive 
rate of 4.2% were observed. The false negative rate of 10.2% suggests that 
detection of a germline mutation is not yet possible for some patients with 
VHL syndrome. Thus, according to MSAC, VHL genetic testing should not 
be used as a stand-alone test for the diagnosis of VHL syndrome in patients 
presenting with VHL-related neoplasms, but as a confirmatory test after 
clinical diagnosis in the index case. The false positive rate of 4.2% was 
expected, as there will always be a few patients who do not meet the criteria 
for clinical diagnosis of VHL syndrome but have an underlying VHL mutation. 
In these patients the disease may not yet have progressed sufficiently to 
obtain a positive clinical diagnosis. 
Table 5 – Median (and range of) diagnostic accuracy data from studies with a low–medium risk of bias for different genetic testing methodologies.3 
Genetic testing methodology Sensitivity Specificity PPV NPV 
Pre-screened DNA sequencing 66.9% (51.8-87.5) 95.0% (88.9-100) 97.8% (85.7-100) 72.2% (30.3-100) 
Direct DNA sequencing 76.9% (44.4-91.4) 100% (57.1-100) 100% (36.0-100) 80.9% (14.3-100) 
Deletion detection (DD) methods 17.4% (3.9-36.6) 100% (100-100) 100% (100-100) 17.1% (4.8-52.4) 
Pre-screened DNA sequencing plus DD 74.6% (14.3-100) 94.9% (50.0-100) 97.1% (54.2-100) 80.0% (12.5-100) 
Direct DNA sequencing (no prescreening) plus DD 100% (70.0-100) 100% (50.0-100) 77.8% (77.8-100) 100% (33.3-100) 
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Genetic diagnosis of a VHL mutation was more accurate in patients with 
phaeochromocytoma than in any other patient group (100% sensitivity in 7/8 
studies).3 This was due to missense VHL mutations (detected by DNA 
sequencing) being the most common cause of phaeochromocytoma in VHL 
syndrome. Patients with phaeochromocytoma (syndromic or sporadic) had 
an overall 7% probability of having an underlying germline VHL mutation, 
whereas patients with familial phaeochromocytoma had a 50% probability of 
having a VHL mutation that is indicative of type 2C VHL syndrome. 
First- or second-degree family members 
Once an index case has a pathogenic VHL mutation identified, their close 
relatives need only be tested for that specific mutation, using a testing 
methodology known to be able to detect that type of mutation.3 Therefore, 
contrary to testing of the index case, the diagnostic accuracy of genetic 
testing within family members did not vary to any great extent by specific 
genetic testing methodology. Every included study reporting accuracy data 
for relatives of someone with a known VHL mutation reported a sensitivity of 
100%. This indicates that, as expected, patients who met the clinical 
diagnostic criteria for VHL syndrome carried the familial VHL mutation. The 
median specificity of 83.3-85.0% and the false positive rates of 16.9-23.5% 
reflect the difference in the timeframe required for a positive clinical 
diagnosis compared with a positive genetic test.3 Younger relatives are more 
likely to receive a positive genetic test before any clinical signs of disease 
can be detected by clinical screening. 
The 100% negative predictive value indicates that a negative genetic test 
result is likely to reflect the true disease status of the patient.3 However, the 
median positive predictive value of 69.4% for first-degree relatives and 
47.8% for first- and second-degree relatives reflects both the potential lag 
between a genetic and clinical diagnosis and the greater prevalence of VHL 
mutation carriers among first-degree relatives compared with second-
degree relatives. That is, it reflects the imperfect nature of the reference 
standard at predicting which relatives would likely develop clinical symptoms 
over time, rather than reflecting poorly on the accuracy of the genetic test. 
Approximately 4 out of 10 of all first- and second-degree relatives, and 2-3 
out of 10 asymptomatic first- and second-degree relatives, who undergo 
VHL genetic testing were identified as carriers of the familial VHL mutation.3 
Change in patient management 
MSAC identified minimal evidence regarding patient management following 
diagnosis of VHL syndrome using genetic testing in combination with clinical 
diagnosis.3 No study provided a direct comparison between patients with a 
known VHL mutation and those that had not been tested. Therefore, due to 
the lack of an appropriate comparator in these studies, no conclusions were 
drawn by MSAC about the change in patient management from genetic 
testing. 
Knowledge of a specific germline VHL mutation in a patient with a clinical 
diagnosis of VHL syndrome may provide some information about the VHL 
syndrome type, which then determines the types of neoplasms that are likely 
to develop in a particular patient. Thus, management of patients with a 
known VHL mutation could be tailored to ensure early detection of the 
neoplasms most likely to occur. Although no difference in patient 
management is expected for patients presenting with the same VHL-
associated neoplasms, based on the method of diagnosis, the VHL genetic 
test is expected to change patient management for asymptomatic relatives 
when used as a triage test for lifelong screening. Relatives with a negative 
genetic test result would not require lifelong screening, saving potential 
anguish and unnecessary use of healthcare resources. Lifelong screening 
programs can then be targeted towards relatives who have inherited the 
VHL mutation and are likely to develop VHL-associated neoplasms. 
While 88.0-97.0% of clinically diagnosed VHL patients agreed to genetic 
testing in the evidence-base, only 58.5-65.8% of at-risk relatives agreed.3 
Additionally, relatives aged over 20 years were more likely to undergo 
genetic testing than children aged less than 5 years, suggesting that parents 
are reluctant to have very young children genetically tested. This reluctance 
appears to diminish with increasing age of the child. Only 38.9% of patients 
with a VHL mutation continued screening after 5 years.3 Symptomatic 
patients were much more likely to continue than asymptomatic patients. 
Patients who have symptoms or have a neoplasm detected early are more 
aware of the personal risks involved than patients who have not developed 
any detectable neoplasms, and thus may be complacent. Whether 
compliance with annual screening is higher with knowledge of a VHL 
mutation than without could not be determined from the available evidence. 
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3.3.1.2 Safety 
MSAC did not identify studies that could inform an assessment of the safety 
of genetic testing in the diagnosis of VHL syndrome or for identification of 
family members with a VHL mutation.3 
3.3.1.3 Cost-effectiveness 
MSAC searched the literature for existing cost-effectiveness analyses, but 
did not identify relevant cost-effectiveness or cost-utility analysis evaluating 
the cost-effectiveness of the use of genetic testing for VHL mutations in 
addition to usual clinical diagnosis in patients suspected of having VHL 
syndrome, or when used as a triage test for lifelong screening of family 
members.3 One study compared the costs and benefits of the use of clinical 
screening only with genetic testing plus clinical screening, and 4 studies 
reported on the costs of clinical screening and VHL genetic testing, and 
found cost savings attributable to the reduction in the number of at-risk 
family members that required clinical screening. The first study also found 
that the use of genetic screening resulted in beneficial psychosocial 
outcomes, for example reduced levels of anxiety associated with the use of 
VHL screening programs and an associated reduction in the likelihood of 
early death of family members. 
In the absence of direct evidence for the increased effectiveness of the 
addition of genetic testing to clinical testing, a conservative assumption of at 
least equal effectiveness was made and a cost comparison was performed 
by MSAC. The analysis considered the costs associated with an individual 
suspected of having VHL syndrome (the index case) and the costs 
associated with testing and monitoring (annual screening) their first- and 
second-degree relatives (who are at risk of having the VHL mutation). The 
first part of the analysis delivers individuals or family members into either 
monitoring or no-monitoring health states based upon the best information 
known from either genetic and clinical testing or clinical testing alone. A 
proportion of family members are assumed to refuse genetic testing (40%) 
and a proportion to refuse monitoring (60%). This non-compliance is a more 
realistic situation than 100% adoption of either testing or monitoring, and is 
important to consider because it will tend to dilute the cost savings 
associated with the genetic testing arm. Those who are genetically positive 
(whether this status is known or unknown) but refuse monitoring will transit 
to a monitoring state once they become symptomatic. 
Due to the high sensitivity and specificity of the genetic test compared with 
a clinical diagnosis, there was very little difference in costs associated with 
managing the index case between the two arms, except for the cost of the 
VHL diagnostic test and the genetic counselling. However, when applied to 
family members, who have an assumed likelihood of carrying the VHL 
mutation of 26%, there is a marked decrease in monitoring among those 
who do not require monitoring (22.1%). Costs of monitoring are assumed to 
be accrued over a lifetime. Treatment costs are assumed to be equivalent 
in both arms. 
The overall cost saving (through avoided inappropriate monitoring) of a 
single index case and their family over their lifetimes is $7 749 in discounted 
costs and $20 783 in undiscounted costs. As there are many uncertainties 
in the analysis, several sensitivity analyses have been performed by MSAC. 
The cost comparison is most sensitive to the prevalence of VHL syndrome 
among patients who are suspected of having it, and the uptake of genetic 
testing and monitoring among family members. In most sensitivity analyses, 
a cost saving remains following the introduction of VHL genetic testing. 
Furthermore, if monitoring and genetic testing rates among family members 
increase, the cost saving associated with genetic testing will markedly 
increase. The cost comparison is not sensitive to moderate changes in the 
proposed reimbursement for VHL genetic testing. 
3.3.2 Overview of published guidelines 
Two consensus-based guidelines contain recommendations about VHL 
mutation testing in patients with the VHL syndrome or their relatives.6, 22 Both 
guidelines lack a good description of their methodology. None of the 
guidelines contains detailed quality appraisal results of the included studies 
or evidence tables. 
Both guidelines recommend VHL mutation analysis in patients with a clinical 
diagnosis of VHL syndrome (Table 6). Furthermore, VHL mutation analysis 
is recommended in first-degree relatives of patients with a known VHL 
mutation, and this at a young age. 
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Table 6 – Overview of published guidelines on VHL mutation testing for the von Hippel-Lindau syndrome. 
Guideline Recommendation AGREE II score ‘Methodology’ 
Binderup 2013 VHL mutation analysis in patients with VHL syndrome 0.0% 
 Full genetic work-up of the family of patients with suspected VHL syndrome  
STOET 2010 VHL mutation analysis in patients with VHL syndrome 6.3% 
 In case of known VHL mutation: VHL mutation analysis in relatives at young age  
Conclusions 
 No direct evidence was identified by MSAC comparing patient health outcomes following genetic testing in addition to usual clinical diagnosis versus usual 
clinical diagnosis alone in patients suspected of having VHL syndrome, or for assessing the effectiveness of VHL genetic testing when used as a triage test 
for life-long screening of family members. 
 No study provided a direct comparison between patients with a known VHL mutation and those that had not been tested. 
 MSAC did not identify studies that could inform an assessment of the safety of genetic testing in the diagnosis of VHL syndrome or for identification of family 
members with a VHL mutation. 
 
Other considerations 
Factor Comment 
Balance between clinical 
benefits and harms 
There is an absence of evidence on harms and benefits. 
Quality of evidence The evidence is limited to studies on diagnostic accuracy (indirect evidence). 
Costs (resource allocation)  VHL mutation testing is billed using the nomenclature code 565515 – 565526 (€353.30 anno 2014). 
 Several recognized Belgian genetic centres provide VHL mutation testing. 
 MSAC calculated that the overall cost saving (through avoided inappropriate monitoring) of a single index case and 
their family over their lifetimes is $7 749 in discounted costs and $20 783 in undiscounted costs (Australian context). 
Patients values and preferences According to the patient representatives, patients with VHL and their relatives should be clearly informed about the risk 
for renal cell carcinoma and other typical manifestations. They should also be informed about the necessary surveillance 
for new manifestations, therapeutic options and fertility planning (if applicable). Psychosocial support should also be 
offered. 
Comments Treatment (including surgery) should not be delayed because of genetic testing.  
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Recommendations Strength of 
Recommendation 
 Pre- and post-test genetic counselling should be offered to all patients with a clinical diagnosis or suspicion of VHL (see box). Strong 
 All patients with a clinical diagnosis of VHL (see box) should be offered VHL genetic testing. Strong 
 In patients with a suspected phenotype of VHL (see box), VHL genetic testing may be considered. Weak 
 Once a germline VHL mutation has been identified in a proband, VHL mutation analysis should be offered to all first-degree 
relatives as soon as possible*. 
Strong 
* Or first-degree relatives of patients with clinical VHL who died before genetic testing was carried out. 
Criteria for clinical diagnosis of VHL 
An individual with no known family history of VHL disease presenting with two or more characteristic lesions: 
 Two or more hemangioblastomas of the retina, spine, or brain or a single hemangioblastoma in association with a visceral manifestation (e.g., multiple 
kidney or pancreatic cysts) 
 Renal cell carcinoma (typically of the clear cell subtype) 
 Adrenal or extra-adrenal pheochromocytoma 
 Less commonly, endolymphatic sac tumour, papillary cystadenoma of the epididymis or broad ligament, or neuroendocrine tumour of the pancreas 
An individual with a positive family history of VHL disease in whom one or more of the following disease manifestations is present:  
 Retinal angioma 
 Spinal or cerebellar hemangioblastoma 
 Adrenal or extra-adrenal pheochromocytoma 
 Renal cell carcinoma (typically of the clear cell subtype) 
 Multiple renal and pancreatic cysts 
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Criteria for clinical suspicion of VHL 
 Isolated central nervous system hemangioblastoma 
 Isolated endolymphatic sac tumour 
 Isolated renal cell carcinoma (typically of the clear cell subtype) at an age < 40 years 
 Multiple renal cell carcinomas (typically of the clear cell subtype) 
 Renal cell carcinoma (typically of the clear cell subtype) and a first- or second-degree relative with a typical VHL-tumour 
 Phaeochromocytoma or paraganglioma (if no SDH mutation) 
 Isolated  papillary cystadenoma of the epididymis 
 Bilateral epididymal cysts 
 Two or more pancreatic serous cystadenomas 
 Two or more pancreatic neuroendocrine tumours 
 Pancreatic serous cystadenoma or neuroendocrine tumour, and first- or second-degree relative with a typical VHL-tumour 
 Multiple pancreatic cysts and another typical VHL-tumour 
  
 KCE Report 242 Oncogenetic testing for endocrine cancer syndromes 35 
 
 
3.4 Paraganglioma and phaeochromocytoma 
3.4.1 Evidence from indexed literature 
Thirty-seven primary studies were included: 18 studies with paraganglioma 
patients,23-40 6 studies with phaechromocytoma patients41-46 and 13 studies 
with a mixed population of paraganglioma and phaeochromocytoma 
patients.47-59 Thirty-five studies reported on clinical and tumour 
characteristics and their relation with the genotype, three studies reported 
on genetic screening of relatives.23, 29, 31 
3.4.1.1 Diagnostic accuracy of individual clinical and tumour 
characteristics for the detection of mutations 
Familial disease 
Twenty-one studies (published in 21 papers) including 6 197 patients 
contained sufficient information to calculate the diagnostic accuracy of 
familial disease for the detection of mutations (Table 7).23, 26, 28, 30, 33, 34, 38-41, 
47-55, 57, 58 For the detection of mutations in patients with paraganglioma 
and/or phaeochromocytoma, familial disease has a high specificity (pooled 
97%, 95%CI 95-99%) and PPV (median 91%), but a low sensitivity (pooled 
43%, 95%CI 33-54%) and NPV (median 76%). With an estimated pre-test 
probability of 30% and on 1 000 evaluated patients, 171 patients without 
familial disease would wrongly be predicted as having no mutation, while 21 
patients with familial disease would wrongly be predicted as having a 
mutation. 
For the detection of SDH mutations in the general population of 
paraganglioma and/or phaeochromocytoma patients, the diagnostic 
accuracy results are similar to the general results, with false negatives of 
around 100 per 1 000 evaluated patients (Table 7). In more specific 
populations, specificity remains high, but the NPV low, resulting in more 
false negative results.  
When specific mutations are considered (i.e. SDHB, SDHC, SDHD, VHL or 
RET), the specificity remains moderate to high, while the NPV becomes 
moderate to high too. This is accompanied by lower false negative results 
for most subpopulations (Table 7). 
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Table 7 – Diagnostic accuracy of ‘familial disease’ for the detection of mutations in patients with paraganglioma and/or phaeochromocytoma. * 
 
* Italic = medians, bold = pooled. $ Medians from unselected populations. 
Multiple tumours 
Seventeen studies including 3 965 patients contained sufficient information 
to calculate the diagnostic accuracy of having multiple tumours for the 
detection of mutations (Table 8).23, 26, 28, 30, 33, 34, 37-39, 41, 45, 51, 53, 56-59 For the 
detection of mutations in patients with paraganglioma and/or 
phaeochromocytoma, having multiple tumours has a high specificity (pooled 
94%, 95%CI 90-96%), a moderate PPV (median 83%), but a low sensitivity 
(pooled 41%, 95%CI 33-50%) and NPV (median 75%). With an estimated 
pre-test probability of 30% and on 1 000 evaluated patients, 177 patients 
with a single tumour would wrongly be predicted as having no mutation, 
while 42 patients with multiple tumours would wrongly be predicted as 
having a mutation. 
For the detection of SDH mutations in the general population of 
paraganglioma and/or phaeochromocytoma patients, the diagnostic 
accuracy results are similar to the general results, with false negatives of 
Median Median Median
Genetic test Population N studies N patients  prevalence Sensitivity * Specificity *  PPV NPV Prevalence $ False negatives False positives
General PHEO/PGL 22 6197 38% 43% 97% 91% 76% 30% 171 21
SDH PHEO/PGL 9 1715 51% 43% 98% 99% 71% 19% 108 16
PGL only 7 1392 42% 54% 99% 99% 71% 48% 221 5
HNPGL 3 641 51% 40% 97% 97% 58% 65% 390 11
Cervical PGL 2 71 38% 55% 100% 100% 78% 38% 171 0
Malignant PHEO/PGL 1 54 43% 9% 90% 40% 57% 43% 391 57
SDHB PHEO/PGL 11 3496 17% 32% 88% 36% 90% 10% 68 108
PGL only 4 1155 24% 38% 80% 33% 82% 21% 130 158
PHEO only 1 989 7% 19% 97% 33% 94% 7% 57 28
HNPGL 2 686 19% 44% 79% 33% 87% 10% 56 189
Malignant PHEO/PGL 1 54 43% 9% 90% 40% 57% 43% 391 57
Parasympathetic PGL 1 24 33% 63% 81% 63% 81% 33% 122 127
SDHC PHEO/PGL 4 1504 3% 6% 88% 2% 97% 1% 9 119
PGL only 2 1043 4% 18% 83% 4% 96% 4% 33 163
HNPGL 1 598 4% 12% 89% 4% 96% 4% 35 106
SDHD PHEO/PGL 11 3499 9% 52% 89% 36% 95% 8% 38 101
PGL only 5 1212 29% 56% 90% 66% 75% 23% 101 77
PHEO only 1 989 3% 11% 96% 7% 97% 3% 27 39
HNPGL 2 686 25% 53% 82% 58% 83% 51% 240 88
Parasympathetic PGL 2 81 43% 51% 85% 69% 70% 43% 211 85
VHL PHEO/PGL 5 2018 5% 28% 86% 13% 96% 6% 43 132
PHEO only 1 989 6% 0% 96% 0% 94% 8% 80 37
RET PHEO/PGL 4 1605 3% 52% 88% 6% 99% 4% 19 115
PHEO only 1 989 3% 0% 96% 0% 97% 5% 50 38
Results per 1 000 patients evaluated
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around 100 per 1 000 evaluated patients (Table 8). In more specific 
populations, specificity remains moderate to high, but the NPV low, resulting 
in more false negative results.  
When specific mutations are considered (i.e. SDHB, SDHC, SDHD, VHL or 
RET), lower specificities are found (with the exception of SDHD), while the 
NPV becomes moderate to high. This is accompanied by lower false 
negative results for most subpopulations (Table 8), but often also more false 
positive results. 
Table 8 – Diagnostic accuracy of ‘multiple tumours’ for the detection of mutations in patients with paraganglioma and/or phaeochromocytoma. * 
 
* Italic = medians, bold = pooled. $ Medians from unselected populations. 
Median Median Median
Genetic test Population N studies N patients  prevalence Sensitivity * Specificity *  PPV NPV Prevalence $ False negatives False positives
General PHEO/PGL 17 3965 35% 41% 94% 83% 75% 30% 177 42
SDH PHEO/PGL 7 1635 41% 52% 92% 92% 78% 19% 91 65
PGL only 6 1366 41% 53% 92% 94% 73% 48% 226 42
HNPGL 3 850 41% 73% 80% 83% 78% 65% 175 70
Cervical PGL 2 71 38% 61% 100% 100% 81% 38% 148 0
SDHB PHEO/PGL 12 3738 9% 21% 82% 8% 92% 10% 79 162
PGL only 5 1353 20% 18% 72% 2% 78% 21% 172 221
PHEO only 2 1260 6% 14% 87% 6% 94% 7% 60 121
HNPGL 2 833 7% 31% 58% 6% 92% 10% 69 378
Parasympathetic PGL 1 24 33% 0% 69% 0% 58% 33% 330 208
SDHC PHEO/PGL 5 2005 2% 17% 83% 0% 97% 1% 8 168
PGL only 2 1043 4% 25% 80% 5% 96% 4% 30 192
HNPGL 1 598 4% 19% 87% 6% 96% 4% 32 192
SDHD PHEO/PGL 13 3795 9% 58% 90% 33% 94% 8% 34 92
PGL only 6 1410 29% 61% 94% 89% 88% 23% 90 46
PHEO only 2 1260 3% 49% 88% 13% 98% 3% 15 116
HNPGL 2 833 49% 67% 75% 79% 61% 51% 168 122
Parasympathetic PGL 2 81 43% 59% 96% 94% 73% 43% 176 23
VHL PHEO/PGL 6 2116 6% 46% 88% 18% 97% 6% 32 113
PHEO only 2 1260 8% 50% 90% 33% 95% 8% 40 92
RET PHEO/PGL 6 2116 3% 50% 87% 10% 98% 4% 20 125
PHEO only 2 1260 4% 55% 88% 16% 98% 5% 22 114
Results per 1 000 patients evaluated
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Bilateral tumours 
Six studies including 1 083 patients contained sufficient information to 
calculate the diagnostic accuracy of having bilateral tumours for the 
detection of mutations (Table 9).37, 40, 48, 50, 51, 59 For the detection of mutations 
in patients with paraganglioma and/or phaeochromocytoma, having bilateral 
tumours has a good pooled specificity (91%, 95%CI 67-98%), but a low 
sensitivity (pooled 37%, 95%CI 23-53%), PPV (median 79%) and NPV 
(median 71%). With an estimated pre-test probability of 30% and on 1 000 
evaluated patients, 189 patients without bilateral tumours would wrongly be 
predicted as having no mutation, while 63 patients with bilateral tumours 
would wrongly be predicted as having a mutation. 
When specific mutations are considered (i.e. SDHB, SDHC, SDHD, VHL or 
RET), lower specificities are found (with the exception of VHL and RET), 
while the NPV becomes moderate to high. This is accompanied by lower 
false negative results for most subpopulations (except for SDHB) (Table 9), 
but often also more false positive results. 
 
Table 9 – Diagnostic accuracy of ‘bilateral tumours’ for the detection of mutations in patients with paraganglioma and/or phaeochromocytoma. * 
 
* Italic = medians, bold = pooled. $ Medians from unselected populations. 
Malignant tumours 
Sixteen studies (published in 15 papers) including 3 656 patients contained 
sufficient information to calculate the diagnostic accuracy of having 
malignancy for the detection of mutations (Table 10).23, 28, 30, 32, 34, 39, 41, 43, 44, 
48, 51, 53, 55, 58, 59 For the detection of mutations in patients with paraganglioma 
and/or phaeochromocytoma, having malignancy has a high specificity 
(pooled 94%, 95%CI 88-97%), but a low sensitivity (pooled 11%, 95%CI 6-
18%), PPV (median 36%) and NPV (median 70%). With an estimated pre-
test probability of 30% and on 1 000 evaluated patients, 267 patients without 
malignancy would wrongly be predicted as having no mutation, while 42 
patients with malignancy would wrongly be predicted as having a mutation. 
For the detection of SDH mutations in the general population of 
paraganglioma and/or phaeochromocytoma patients, the diagnostic 
accuracy results are similar to the general results, with false negatives of 
167 per 1 000 evaluated patients (Table 10). In more specific populations, 
specificity remains moderate to high (with the exception of sympathetic 
paraganglioma), but the NPV low, resulting in more false negative results.  
When specific mutations are considered (i.e. SDHB, SDHC, SDHD, VHL or 
RET), also moderate to high specificities are found, while the NPV becomes 
moderate to high too. This is accompanied by lower false negative results 
for most subpopulations (Table 10), and often acceptable false positive 
results. 
Median Median Median
Genetic test Population N studies N patients  prevalence Sensitivity * Specificity *  PPV NPV Prevalence $ False negatives False positives
General PHEO/PGL 6 1083 32% 37% 91% 79% 71% 30% 189 63
SDH HNPGL 1 26 62% 81% 80% 87% 73% 65% 123 70
SDHB PHEO/PGL 4 1004 12% 0% 74% 0% 82% 10% 100 234
Sporadic PGL 1 51 20% 0% 85% 0% 78% 20% 200 120
SDHC PHEO/PGL 2 639 0,5% 0% 59% 0% 99% 1% 10 406
SDHD PHEO/PGL 4 1004 7% 17% 83% 5% 91% 8% 66 156
Sporadic PGL 1 51 18% 56% 98% 83% 91% 18% 79 16
VHL PHEO/PGL 3 953 6% 68% 89% 20% 97% 6% 19 103
RET PHEO/PGL 3 953 5% 69% 90% 27% 98% 4% 12 96
Results per 1 000 patients evaluated
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Table 10 – Diagnostic accuracy of ‘malignant tumours’ for the detection of mutations in patients with paraganglioma and/or phaeochromocytoma. * 
 
* Italic = medians, bold = pooled. $ Medians from unselected populations. 
Metastatic disease 
Four studies including 534 patients contained sufficient information to 
calculate the diagnostic accuracy of having metastatic disease for the 
detection of SDH mutations (Table 11).24, 25, 40, 57 For the detection of SDH 
mutations in patients with paraganglioma and/or phaeochromocytoma, 
having metastatic disease has a high specificity (median 93%, range 80-
100%), but a low sensitivity (median 13%, range 11-31%), PPV (median 
71%) and NPV (median 70%). With an estimated pre-test probability of 19% 
and on 1 000 evaluated patients, 165 patients without metastatic disease 
would wrongly be predicted as having no SDH mutation, while 57 patients 
with metastatic disease would wrongly be predicted as having a SDH 
mutation. 
When specific mutations are considered (i.e. SDHB, SDHC, SDHD), a high 
specificity and NPV are found for SDHC and SDHD (1 study), but a low to 
moderate specificity and a low NPV for SDHB. This is accompanied by lower 
false negative results and acceptable false positive results for SDHC and 
SDHD (Table 11), but not for SDHB. 
Median Median Median
Genetic test Population N studies N patients  prevalence Sensitivity * Specificity *  PPV NPV Prevalence $ False negatives False positives
General PHEO/PGL 16 3656 32% 11% 94% 36% 70% 30% 267 42
SDH PHEO/PGL 5 900 41% 12% 97% 52% 59% 19% 167 24
HNPGL 3 850 41% 2% 100% 83% 59% 65% 637 0
Cervical PGL 1 23 35% 13% 87% 33% 65% 38% 331 81
Sympathetic PGL 1 27 41% 55% 38% 38% 55% 43% 193 353
SDHB PHEO/PGL 11 3546 11% 25% 94% 29% 91% 10% 75 54
PGL only 4 945 19% 6% 97% 17% 82% 21% 197 24
PHEO only 2 1071 7% 55% 86% 23% 96% 7% 31 130
HNPGL 3 921 11% 4% 97% 33% 91% 10% 96 27
Parasympathetic PGL 1 24 33% 0% 94% 0% 65% 33% 330 40
SDHC PHEO/PGL 3 1291 1% 0% 94% 0% 99% 1% 10 59
HNPGL 1 598 4% 0% 94% 0% 95% 4% 40 58
SDHD PHEO/PGL 10 3464 9% 5% 92% 7% 89% 8% 76 74
PGL only 4 645 32% 4% 97% 30% 67% 23% 221 23
PHEO only 1 989 3% 4% 91% 1% 97% 3% 29 87
HNPGL 3 921 35% 3% 96% 33% 65% 51% 495 20
Parasympathetic PGL 1 24 29% 0% 94% 0% 70% 43% 430 34
VHL PHEO/PGL 7 2534 6% 6% 88% 4% 93% 6% 56 113
PHEO only 2 1004 6% 4% 88% 2% 93% 8% 77 110
RET PHEO/PGL 6 2121 4% 0% 91% 0% 95% 4% 40 86
PHEO only 2 1004 3% 0% 91% 0% 97% 5% 50 86
Results per 1 000 patients evaluated
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Table 11 – Diagnostic accuracy of ‘metastatic disease’ for the detection of SDH mutations in patients with paraganglioma and/or 
phaeochromocytoma. * 
 
* Italic = medians, bold = pooled. $ Medians from unselected populations. 
Recurrence 
Four smaller studies including 176 patients contained sufficient information 
to calculate the diagnostic accuracy of recurrent disease for the detection of 
mutations (Table 12).33, 37, 39, 59 For the detection of mutations in patients with 
paraganglioma and/or phaeochromocytoma, recurrent disease has a high 
specificity (pooled 92%, 95%CI 77-97%), but a low sensitivity (pooled 12%, 
95%CI 3-38%), PPV (median 57%) and NPV (median 61%). With an 
estimated pre-test probability of 30% and on 1 000 evaluated patients, 264 
patients without recurrence would wrongly be predicted as having no 
mutation, while 56 patients with recurrence would wrongly be predicted as 
having a mutation. 
When specific mutations are considered (i.e. SDHB, SDHC, SDHD, VHL or 
RET), also moderate to high specificities are found, but the NPV remains 
low (with the exception of VHL and RET, 1 small study). This is accompanied 
by high false negative results for most subpopulations (again with the 
exception of VHL and RET, 1 small study) (Table 12). 
 
 
Median Median Median
Genetic test Population N studies N patients  prevalence Sensitivity * Specificity *  PPV NPV Prevalence $ False negatives False positives
SDH PHEO/PGL 3 490 32% 13% 93% 71% 70% 19% 165 57
HNPGL 2 221 47% 21% 90% 86% 56% 65% 513 35
SDHB PHEO/PGL 2 313 24% 29% 82% 34% 77% 10% 71 162
Malignant PGL 1 44 41% 33% 69% 43% 60% 41% 275 183
SDHC PHEO/PGL 1 269 8% 0% 92% 0% 92% 1% 10 79
SDHD PHEO/PGL 1 269 5% 0% 92% 0% 95% 8% 80 74
Results per 1 000 patients evaluated
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Table 12 – Diagnostic accuracy of ‘recurrent disease’ for the detection of mutations in patients with paraganglioma and/or phaeochromocytoma. * 
 
* Italic = medians, bold = pooled. $ Medians from unselected populations. 
Extra-adrenal disease 
Nine studies including 2 379 patients contained sufficient information to 
calculate the diagnostic accuracy of having extra-adrenal disease for the 
detection of mutations (Table 13).30, 41, 43-45, 48, 53, 55, 59 For the detection of 
mutations in patients with paraganglioma and/or phaeochromocytoma, 
having extra-adrenal disease has a moderate specificity (pooled 89%, 
95%CI 82-93%), but a low sensitivity (pooled 26%, 95%CI 16-38%), PPV 
(median 44%) and NPV (median 77%). With an estimated pre-test 
probability of 30% and on 1 000 evaluated patients, 222 patients without 
extra-adrenal disease would wrongly be predicted as having no mutation, 
while 77 patients with extra-adrenal disease would wrongly be predicted as 
having a mutation. 
When specific mutations are considered (i.e. SDHB, SDHC, SDHD, VHL or 
RET), mostly moderate specificities are found (with the exception for the 
head and neck paragangliomas), while the NPV becomes high. This is 
accompanied by lower false negative results for most subpopulations (Table 
13), but the false positive results remain above 100. 
 
 
Median Median Median
Genetic test Population N studies N patients  prevalence Sensitivity * Specificity *  PPV NPV Prevalence $ False negatives False positives
General PHEO/PGL 4 176 39% 12% 92% 57% 61% 30% 264 56
SDH Cervical PGL 1 48 42% 35% 86% 64% 65% 38% 247 87
SDHB PHEO/PGL 3 128 20% 0% 94% 0% 78% 10% 100 54
PGL only 2 75 26% 6% 90% 25% 73% 21% 197 79
Parasympathetic PGL 1 24 33% 13% 94% 50% 68% 33% 287 40
SDHC -
SDHD PHEO/PGL 4 185 23% 12% 92% 25% 76% 8% 70 74
PGL only 3 132 29% 13% 88% 50% 73% 23% 200 92
Parasympathetic PGL 2 81 43% 13% 91% 54% 58% 43% 374 51
VHL PHEO/PGL 1 53 2% 100% 98% 50% 100% 6% 0 19
RET PHEO/PGL 1 53 4% 0% 96% 0% 96% 4% 40 38
Results per 1 000 patients evaluated
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Table 13 – Diagnostic accuracy of ‘extra-adrenal disease’ for the detection of mutations in patients with paraganglioma and/or phaeochromocytoma.* 
 
* Italic = medians, bold = pooled. $ Medians from unselected populations. 
Secretory tumours 
Four studies including 568 patients contained sufficient information to 
calculate the diagnostic accuracy of having a secretory tumour for the 
detection of mutations (Table 14).23, 39, 40, 58 For the detection of mutations in 
patients with paraganglioma and/or phaeochromocytoma, having a 
secretory tumour has a low specificity (pooled 78%, 95%CI 36-96%), 
sensitivity (pooled 24%, 95%CI 6-62%), PPV (median 50%) and NPV 
(median 51%). With an estimated pre-test probability of 30% and on 1 000 
evaluated patients, 228 patients without a secretory tumour would wrongly 
be predicted as having no mutation, while 154 patients with a secretory 
tumour would wrongly be predicted as having a mutation. 
When specific mutations are considered (i.e. SDHB, SDHC, SDHD, VHL or 
RET), mostly low specificities are found, while the NPV becomes high (with 
the exception of SDHB and SDHD). This is accompanied by lower false 
negative results (Table 14), but the false positive results remain high. 
 
Median Median Median
Genetic test Population N studies N patients  prevalence Sensitivity * Specificity *  PPV NPV Prevalence $ False negatives False positives
General PHEO/PGL 9 2379 25% 26% 89% 44% 77% 30% 222 77
SDH HNPGL 1 157 89% 7% 100% 100% 12% 65% 604 0
SDHB PHEO/PGL 8 2392 8% 56% 86% 30% 95% 10% 44 126
PHEO only 3 1344 7% 63% 87% 28% 97% 7% 26 121
HNPGL 1 157 5% 0% 93% 0% 95% 10% 100 63
Malignant PHEO/PGL 1 54 43% 70% 71% 64% 76% 43% 129 165
SDHC -
SDHD PHEO/PGL 6 2254 4% 31% 85% 11% 97% 8% 55 138
PHEO only 2 1260 3% 49% 87% 12% 98% 3% 15 126
HNPGL 1 157 81% 8% 100% 100% 20% 51% 469 0
VHL PHEO/PGL 6 2112 6% 22% 81% 6% 93% 6% 47 179
PHEO only 3 1275 7% 13% 86% 6% 92% 8% 70 129
RET PHEO/PGL 5 1699 5% 0% 82% 0% 95% 4% 40 173
PHEO only 3 1275 5% 0% 85% 0% 95% 5% 50 142
Results per 1 000 patients evaluated
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Table 14 – Diagnostic accuracy of ‘secretory tumours’ for the detection of mutations in patients with paraganglioma and/or phaeochromocytoma. * 
 
* Italic = medians, bold = pooled. $ Medians from unselected populations. 
Head-and-neck location 
Seven studies including 2 012 patients contained sufficient information to 
calculate the diagnostic accuracy of a head-and-neck location for the 
detection of mutations (Table 15).26, 33, 50, 51, 53, 55, 57 For the detection of 
mutations in patients with paraganglioma and/or phaeochromocytoma, a 
head-and-neck location has a low specificity (pooled 70%, 95%CI 32-92%), 
sensitivity (pooled 45%, 95%CI 23-70%), PPV (median 49%) and NPV 
(median 64%). With an estimated pre-test probability of 30% and on 1 000 
evaluated patients, 165 patients without a head-and-neck location would 
wrongly be predicted as having no mutation, while 210 patients with a head-
and-neck location would wrongly be predicted as having a mutation. 
For the detection of SDH mutations in the general population of 
paraganglioma and/or phaeochromocytoma patients, the diagnostic 
accuracy results are contradictory to the general results, with false negatives 
of 47 per 1 000 evaluated patients (but more false positives) (Table 15). In 
more specific populations, specificity and NPV remain low.  
When specific mutations are considered (i.e. SDHB, SDHC, SDHD, VHL or 
RET), also low to moderate specificities are found, while the NPV becomes 
high (with the exception of SDHB). This is accompanied by lower false 
negative results for most subpopulations (Table 15), but still high false 
positive results. 
Median Median Median
Genetic test Population N studies N patients  prevalence Sensitivity * Specificity *  PPV NPV Prevalence $ False negatives False positives
General PHEO/PGL 4 568 51% 24% 78% 50% 51% 30% 228 154
SDH HNPGL 2 43 51% 21% 90% 75% 52% 65% 513 35
SDHB PHEO/PGL 3 579 33% 83% 21% 5% 64% 10% 17 711
Parasympathetic PGL 1 24 33% 0% 88% 0% 64% 33% 330 80
Malignant PHEO/PGL 1 54 43% 83% 6% 40% 33% 43% 73 536
SDHC PHEO/PGL 1 501 1% 25% 21% 0% 97% 1% 7 782
SDHD PHEO/PGL 2 525 19% 35% 56% 28% 76% 8% 52 405
Parasympathetic PGL 1 24 29% 14% 94% 50% 73% 43% 370 34
VHL PHEO/PGL 1 501 10% 96% 23% 12% 98% 6% 2 724
RET PHEO/PGL 1 501 5% 100% 22% 7% 100% 4% 0 749
Results per 1 000 patients evaluated
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Table 15 – Diagnostic accuracy of ‘head-and-neck location’ for the detection of mutations in patients with paraganglioma and/or 
phaeochromocytoma. * 
 
* Italic = medians, bold = pooled. $ Medians from unselected populations. 
Age 
Seven studies including 2 442 patients contained sufficient information to 
calculate the diagnostic accuracy of different age cut-offs for the detection 
of mutations (Table 16).26, 34, 39, 41, 44-46 Only the age categories <18y and 
<20y appear to have a moderate to high specificity in combination with a 
moderate to high NPV, but an ideal combination of false negative and 
positive results is never available. 
 
 
Median Median Median
Genetic test Population N studies N patients  prevalence Sensitivity * Specificity *  PPV NPV Prevalence $ False negatives False positives
General PHEO/PGL 7 2012 39% 45% 70% 49% 64% 30% 165 210
SDH PHEO/PGL 3 762 42% 75% 27% 42% 48% 19% 47 591
PGL only 2 493 48% 83% 14% 47% 48% 48% 82 380
Cervical PGL 1 48 42% 90% 0% 39% 0% 38% 38 620
SDHB PHEO/PGL 6 1964 15% 23% 82% 17% 85% 10% 77 162
PGL only 1 445 22% 43% 17% 12% 52% 21% 120 656
SDHC PHEO/PGL 4 1353 1% 75% 75% 4% 99% 1% 2 248
PGL only 1 445 4% 88% 26% 4% 98% 4% 5 710
SDHD PHEO/PGL 6 1964 8% 79% 82% 29% 97% 8% 17 166
PGL only 1 445 29% 98% 36% 38% 97% 23% 5 493
VHL PHEO/PGL 4 1220 5% 3% 81% 0% 94% 6% 58 179
RET PHEO/PGL 3 749 3% 0% 79% 0% 97% 4% 40 202
Results per 1 000 patients evaluated
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Table 16 – Diagnostic accuracy of different age cut-offs for the detection of mutations in patients with paraganglioma and/or phaeochromocytoma. * 
 
* Italic = medians, bold = pooled. $ Medians from unselected populations. 
3.4.1.2 Published models and proposed screening algorithms 
Three articles report on the development of an algorithm for genetic 
screening. Erlic et al. retrospectively included 989 patients with apparently 
non-syndromic phaeochromocytoma, and tested them for germline 
mutations in the genes SDHB, SDHC, SDHD, VHL and RET.41 Clinical 
parameters (age, gender, tumour number, tumour biology [benign vs. 
malignant], tumour location [adrenal, extra-adrenal, and concomitant 
adrenal with extra-adrenal], previous head-and-neck paraganglioma, and 
family history for paraganglial tumours) were analyzed as potential 
predictors for finding mutations by multiple logistic regression, validated by 
bootstrapping. Predictors for the presence of any mutation were age <45 
years (OR 5.37, 95%CI 3.34 to 8.62), multiple pheochromocytoma (OR 8.78, 
95%CI 5.47 to 14.08), extra-adrenal location (OR 4.93, 95%CI 3.00 to 8.10), 
and previous head-and-neck paraganglioma (OR 11.95, 95%CI 3.15 to 
45.32). If the presence of any one predictor was used as indicative of 
proceeding with genetic testing, then 342 (34.6%) patients would be 
excluded, and only 8 carriers (4.3%) would be missed. The performance of 
the model was: sensitivity 95.7%, specificity 41.6%, PPV 23.0% and NPV 
97.7%. Based on their analysis the authors also proposed an algorithm 
including a priority of genes to be tested according to specific clinical 
features (Figure 5). Importantly, this model has not been validated in an 
independent cohort. 
 
Median Median Median
Genetic test Age cut-off Population N studies N patients  prevalence Sensitivity *Specificity *  PPV NPV Prevalence $ False negatives False positives
General <18y PHEO only 1 271 24% 41% 90% 56% 83% 24% 142 76
<20y PHEO/PGL 1 100 8% 13% 98% 33% 93% 30% 261 14
<40y PHEO/PGL 2 124 35% 58% 37% 33% 55% 30% 126 441
<45y PHEO only 2 1004 19% 59% 69% 32% 89% 24% 98 236
SDH <35y PGL only 1 445 54% 55% 83% 80% 61% 48% 216 88
<40y HNPGL 1 598 31% 59% 79% 55% 81% 65% 266 74
SDHB <18y PHEO only 1 271 4% 33% 83% 8% 96% 7% 47 158
<35y PGL only 1 445 22% 50% 66% 29% 83% 21% 105 269
<40y PGL only 2 622 22% 59% 44% 23% 72% 21% 86 442
<45y PHEO only 1 989 7% 77% 49% 11% 96% 7% 16 474
SDHC <35y PGL only 1 445 4% 38% 63% 4% 96% 4% 25 355
<40y HNPGL 1 598 4% 58% 69% 8% 97% 4% 17 298
SDHD <18y PHEO only 1 271 4% 27% 83% 6% 96% 3% 22 165
<35y PGL only 1 445 29% 60% 72% 47% 81% 23% 92 216
<40y PGL only 2 622 22% 67% 48% 29% 79% 23% 76 400
<45y PHEO only 1 989 3% 96% 49% 5% 100% 3% 1 495
VHL <18y PHEO only 1 271 11% 67% 88% 42% 96% 8% 26 110
<45y PHEO only 2 1004 6% 47% 64% 5% 96% 8% 42 331
RET <18y PHEO only 1 271 5% 0% 81% 0% 94% 5% 50 180
<45y PHEO only 2 1004 8% 62% 66% 19% 95% 5% 19 323
Results per 1 000 patients evaluated
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Figure 5 – Genetic testing algorithm for apparently non-syndromic phaeochromocytoma, proposed by Erlic et al.41 
  
HNP: head-and-neck paraganglioma. 
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Jafri et al. prospectively included 501 patients with non-syndromic 
phaeochromocytoma, paraganglioma and head-and-neck paraganglioma.55 
Patients were tested for germline mutations in the genes SDHB, SDHD and 
VHL. Mutation detection rates were highest in those with a positive family 
history (62%), malignancy (53%), multiple tumours (33%) or paraganglioma 
(44%). Jafri et al. developed three models, each including positive family 
history, multiple tumours, extra-adrenal location and/or malignant disease, 
but with different age cut-offs (45y, 50y and 60y). While the model including 
the 45y cut-off achieved an overall mutation detection rate of 69% (97% of 
SDHD mutations, 95% of VHL mutations and 76% of SDHB mutations), the 
detection rate increased to 69.1% with the 50y cut-off and 76.4% with the 
60y cut-off. However, this was at the cost of an increased number of tests 
undertaken. Again, this model was not validated in an independent cohort. 
Finally, Neumann et al. included 598 patients with head-and-neck 
paraganglioma and tested them for germline mutations in the genes SDHB, 
SDHC and SDHD.34 Six variables (age, gender, number of tumors [solitary 
or multiple], tumour biology [malignant or benign), previous paraganglial 
tumours, and family history for head-and-neck paraganglioma or 
pheochromocytoma) were included in a logistic regression model. Based on 
the model an algorithm was developed to identify which patients should be 
genetically tested for mutations. Bootstrap analysis was performed to 
assess the performance of the logistic regression model and the predictive 
ability of the testing algorithm, and to calculate the cost-reduction of our 
proposed testing strategy. Multiple logistic regression analysis indicated that 
5 of the 6 variables (not tumour biology) included in the model were 
independently associated with presence of a germline mutation in one of the 
SDHx genes. If the presence of any one predictor was used as indicative of 
proceeding with genetic testing, then 272 (45.5%) patients would be 
excluded, and 15 carriers (8.2%) would be missed. The performance of the 
model was: sensitivity 91.8%, specificity 61.9%, PPV 51.5% and NPV 
94.5%. The proposed algorithm is presented in Figure 6. This model was 
also not validated in an independent cohort. 
Several other authors proposed genetic testing algorithms, although not 
based on multivariate analysis and modelling, but only based on univariate 
analysis (see appendix 6).43, 48, 53, 54, 58 Most of these algorithms include as a 
first step the distinction between familial and/or syndromic cases versus 
sporadic cases. In cases with a familial and/or syndromic presentation, 
targeted genetic testing is recommended based on clinical features (e.g. 
RET testing in case of medullary thyroid carcinoma, VHL testing in case of 
hemangioblastoma, etc). For the apparently sporadic cases, the algorithms 
show some differences. For example only two algorithms include an age cut-
off (30y 53 and 35y 43). Most other clinical variables (head-and-neck location, 
malignant disease, extra-adrenal disease, multiple tumours, recurrence, etc) 
are not consistently used. 
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Figure 6 – Genetic testing algorithm for apparently non-syndromic phaeochromocytoma, proposed by Neumann et al.34 
 
HNP: head-and-neck paraganglioma.  
 KCE Report 242 Oncogenetic testing for endocrine cancer syndromes 49 
 
 
3.4.1.3 Genetic screening of relatives 
Bacca et al. screened 17 relatives of 4 unrelated patients with a non-
syndromic head-and-neck paraganglioma and a known mutation of the 
SDHB, SDHC, SDHD, SDHAF2, VHL and RET genes.23 Ten cases (58.8%; 
age range 17-71y) were found to carry a SDHD mutation, four of these 
(belonging to two families with the same type of mutation) were clinically 
affected. The remaining seven relatives were disease-free, but no indication 
was given about the duration of follow-up. 
Hensen et al. included 243 relatives of a seven-generation family with head-
and-neck paragangliomas and a D92Y missense mutation in the SDHD 
gene.29 Of the 211 family members that were alive (6th and 7th generation), 
189 accepted genetic testing. Of these, 63 tested positive (33%) and one 
other relative (that could not be tested) was found to be an obligate carrier 
(because of an affected offspring). In total, 53 paternal and 11 maternal 
mutation carriers were found. Using a Kaplan-Meier analysis, the authors 
calculated an overall clinical penetrance of 57% (30 symptomatic 
paragangliomas) with a maximum reached at 47y. The overall penetrance 
was 68% (an additional six paragangliomas detected with MRI screening), 
increasing to 87% at 70y. 
Finally, Hes et al. included 19 relatives of an index patient with an extra-
adrenal paraganglioma and a confirmed SDHB mutation.31 Fourteen 
relatives (73.7%) were found to be mutation carriers. Of these eleven 
underwent clinical screening and two were identified with subclinical vagal 
paragangliomas. Penetrance, calculated with a Kaplan-Meier analysis, was 
26% at 48y. 
3.4.1.4 Impact of genetic screening on outcomes 
No studies were found that reported on the impact of genetic screening on 
clinical outcomes of patients with phaeochromocytoma and/or 
paraganglioma and their relatives. 
3.4.1.5 SDH immunohistochemistry 
Five studies including 386 patients with phaeochromocytoma and/or 
paraganglioma evaluated the diagnostic accuracy of SDHB immunostaining 
for the detection of SDH mutations.60-63 Two studies, a retrospective and a 
prospective, were reported in one article.63  For the detection of SDH 
mutations in general, SDHB immunostaining has a high sensitivity (median 
100%) and specificity (median 93%, range 84-97%), a moderate PPV 
(median 82%, range 67-96%) and a high NPV (median 100%) (Table 17). 
With an estimated pre-test probability of 20% and on 1 000 evaluated 
patients, no patient with positive SDHB immunostaining would wrongly be 
predicted as having no SDH mutation, while 56 patients with negative SDHB 
immunostaining would wrongly be predicted as having a SDH mutation. 
When specific mutations are considered (i.e. SDHB, SDHC, SDHD), also 
high sensitivities and NPV are found, but the specificities and PPV become 
clearly lower. This is accompanied by no false negative results (Table 17), 
but higher false positive results. 
Table 17 – Diagnostic accuracy of SDH immunohistochemistry for the detection of SDH mutations in patients with paraganglioma and/or 
phaeochromocytoma. * 
 
* Italic = medians, bold = pooled. $ Medians from unselected populations. 
Median Median Median
Genetic test Population N studies N patients  prevalence Sensitivity * Specificity *  PPV NPV Prevalence $ False negatives False positives
SDH PHEO/PGL 5 386 22% 100% 93% 82% 100% 20% 0 56
SDHB PHEO/PGL 4 341 12% 100% 80% 42% 100% 10% 0 180
SDHC PHEO/PGL 2 233 2% 100% 66% 6% 100% 1% 0 337
SDHD PHEO/PGL 4 341 8% 100% 78% 33% 100% 8% 0 202
Results per 1 000 patients evaluated
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3.4.2 Overview of published guidelines 
Three consensus-based guidelines contain recommendations about 
mutation testing in patients with phaeochromocytoma / paraganglioma or 
their relatives.4, 6, 64 The AACE 2009 and STOET 2010 guidelines lack a 
good description of their methodology. The Endocrine Society 2014 
guideline contains a more detailed description of the used methodology, but 
still clearly is consensus-based. None of the guidelines contains detailed 
quality appraisal results of the included studies or evidence tables. 
Both the Endocrine Society 2014 and STOET 2010 guidelines recommend 
the use of clinical features to guide mutation testing (Table 18). However, 
only the Endocrine Society 2014 guideline contains a specific and clear 
algorithm (Figure 7). Similar to previously mentioned algorithms, targeted 
genetic testing is recommended in case of a syndromic presentation. 
However, clinical features that are not used in previously mentioned 
algorithms are metastatic disease and biochemical presentation. 
  
 KCE Report 242 Oncogenetic testing for endocrine cancer syndromes 51 
 
 
Table 18 – Overview of published guidelines on mutation testing for phaeochromocytoma / paraganglioma. 
Guideline Recommendation AGREE II score 
‘Methodology’ 
Endocrine 
Society 2014 
We recommend that all patients with PPGLs should be engaged in shared decision making for genetic testing 29.2% 
 We recommend the use of a clinical feature-driven diagnostic algorithm to establish the priorities for specific genetic 
testing in PPGL patients with suspected germline mutations 
 
 We suggest that patients with paraganglioma undergo testing of SDH mutations and that patients with metastatic 
disease undergo testing for SDHB mutations 
 
 We recommend that genetic testing for PPGL be delivered within the framework of health care. Specifically, pretest 
and post-test counseling should be available. All tests for PPGL genetic testing should be performed by accredited 
laboratories 
 
AACE 2009 About one-quarter of patients with a pheochromocytoma will have associated familial syndromes caused by mutations 
in the RET gene (multiple endocrine neoplasia type 2), VHL gene (von Hippel-Lindau disease), or succinate 
dehydrogenase genes; genetic study and counseling should be performed, especially for young patients or patients 
with an extra-adrenal pheochromocytoma 
16.7% 
STOET 2010 SDH 6.3% 
 SDH mutation analysis in patients with: 
 Head-and-neck paraganglioma 
 Phaeochromocytoma and familial head-and-neck paraganglioma / phaeochromocytoma 
 Sporadic phaeochromocytoma < 50y 
 
 Order of testing: SDHD, SDHB, SDHC (driven by clinical features: extra-adrenal and malignant phaeochromocytoma 
first SDHB) 
 
 In case of known SDH mutation: SDH mutation analysis in relatives at young adult age  
 RET  
 RET mutation analysis in patients with sporadic phaeochromocytoma <50y  
 In case of known RET mutation: RET mutation analysis in first-degree relatives at young age (0-5 years)  
 VHL  
 VHL mutation analysis in patients with VHL syndrome and phaeochromocytoma  
 In case of known VHL mutation: VHL mutation analysis in relatives at young age  
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Figure 7 – Genetic testing algorithm for phaeochromocytoma and paraganglioma, proposed by the Endocrine Society.4 
 
PPGL: phaeochromocytoma / paraganglioma.  
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Conclusions 
 No validated models / algorithms exist for genetic testing of patients with phaeochromocytoma and/or paraganglioma.  
 The available algorithms generally agree on the use of clinical features to guide mutation testing. However, they disagree on which clinical features to be 
used in priority. In case of a syndromic presentation, targeted genetic testing is recommended by most algorithms. 
 No single clinical feature has a good diagnostic accuracy to guide mutation testing. 
 SDHB immunostaining has a high sensitivity and negative predictive value for the detection of SDH mutations in patients with phaeochromocytoma and/or 
paraganglioma. 
 The evidence on genetic screening of relatives is limited. 
 No studies were found that reported on the impact of genetic screening on clinical outcomes. 
 
Other considerations 
Factor Comment 
Balance between clinical 
benefits and harms 
No evidence was found on harm from genetic testing of patients with phaeochromocytoma and/or paraganglioma. 
However, also no evidence was found on the impact of genetic screening on clinical outcomes. No validated models 
were found either. 
The expected benefits of genetic testing in patients with phaeochromocytoma / paraganglioma are (1) a confirmation of 
the diagnosis as such, (2) the identification of the need for targeted surveillance for other syndrome-associated tumours 
(mainly in case of a syndromic presentation), and (3) the identification of the need of first-degree relatives to undergo 
genetic counselling and testing.  
Genetic screening of relatives can preclude mutation-negative relatives from annual clinical screening. Mutation-positive 
relatives will enter surveillance programmes targeted at early diagnosis of these tumours (and/or other syndrome-
associated tumours in case of a syndromic presentation). 
Quality of evidence Only indirect evidence of very low quality is available. 
Costs (resource allocation)  VHL and RET mutation testing are billed using the nomenclature code 565515 – 565526 (€353.30 anno 2014). SDH 
testing (i.e. SDHB, SDHC and SDHD) is billed using the nomenclature code 565530 – 565541 (€552.47 anno 2014). 
SDH immunohistochemistry is billed using the nomenclature code 588070 – 588081 (€26.02 anno 2014). 
 Several recognized Belgian genetic centres provide these tests. 
 54  Oncogenetic testing for endocrine cancer syndromes KCE Report 242 
 
 
Factor Comment 
Patients values and preferences No specific comments were received, but in general the comments made for MEN2, MEN1 and VHL also apply to 
patients with  phaeochromocytoma / paraganglioma. 
Comment (1) This report focused on genetic testing for SDHx genes (SDHD + SDHB + SDHC), VHL and RET. However, in 
patients with phaeochromocytoma / paraganglioma and clinical features (i.e. age < 35 years, metastatic disease, 
recurrent disease, bilateral tumours and/or familial disease) suggestive of a mutation who test negative for SDHx, 
VHL and RET, further genetic testing may be considered (as part of research). The following list contains other 
potentially affected genes: 
 NF1 
 SDHA 
 SDHAF2 
 TMEM127 
 MAX 
 EPAS1 (test not available in Belgium) 
 FH (test not available in Belgium) 
(2) As genetic technologies develop rapidly, panel-based tests are becoming more common. This is especially true for 
diseases with large genetic heterogeneity (i.e. when mutations in a number of genes can cause the same disease). 
Panel-based genetic tests allow to obtain results for multiple genes in one session. This will likely influence genetic 
testing of phaeochromocytoma / paraganglioma in the future. 
(3) Because of a lack of evidence and because of clarity reasons, it was opted not to include functionality in our 
recommendations. 
(4) Treatment (including surgery) should not be delayed because of genetic testing. 
 
Recommendations Strength of 
Recommendation 
 Pre- and post-test genetic counselling should be offered to all patients with phaeochromocytoma / paraganglioma. Strong 
 In patients with phaeochromocytoma / paraganglioma and syndromic features, targeted genetic testing (e.g. for MEN2 and VHL) 
should be offered. 
Strong 
 All patients with phaeochromocytoma / paraganglioma that lack syndromic features should be offered genetic testing for SDHx 
genes (SDHD + SDHB + SDHC), VHL and RET (in this order). 
Strong 
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Recommendations Strength of 
Recommendation 
 If tumour tissue is available, SDHB immunohistochemistry testing could be considered as a triage test before proceeding with 
genetic testing for SDHx genes. 
Weak 
 In patients with phaeochromocytoma / paraganglioma and clinical features suggestive of a mutation (i.e. age < 35 years, 
metastatic disease, recurrent disease, bilateral tumours and/or familial disease), who test negative for SDHx, VHL and RET, 
further genetic testing may be considered. 
Weak 
 Once a germline mutation has been identified in a proband, mutation analysis should be offered to all first-degree relatives 
irrespective of age. 
Strong 
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4 IMPLEMENTATION AND UPDATING OF 
THE GUIDELINE 
4.1 Implementation 
4.1.1 Multidisciplinary approach  
In this report we focused on the effectiveness of specific diagnostic 
interventions. In clinical practice, a multidisciplinary approach by different 
health care professionals should be encouraged. This approach should not 
only cover the medical needs of the patients but also their psychosocial 
needs. 
4.1.2 Patient-centered care 
The choice of an intervention, e.g. germline mutation analysis, should not 
only consider medical aspects but also psychosocial consequences and 
patient preferences. Patients’ representatives ask that a correct and 
understandable information be provided to individuals at increased genetic 
risk (within the philosophy of the Belgian law on patients rights of 26 
September 2002). Continued support in decision-making is important during 
the different phases of the process (referral, testing, steps after a positive or 
a negative test). It is important to clearly explain figures about the increased 
risk of cancer. Balanced and understandable information about the pros and 
cons of the various decisions has to be provided (e.g. about clinical 
surveillance or prophylactic surgery). There is a need for psychosocial 
support (by professionals and by fellow patients if possible) when making 
choices, when informing children and family members about the genetic 
predisposition or with respect to fertility planning. A uniform policy followed 
by all Genetic Centres in Belgium is essential. It is important that general 
practitioners / oncologists / endocrinologists / psychologists are well 
informed about where to refer patients with these rare syndromes and 
tumours. According to the patients’ representatives, a lot of people are 
currently not referred or do not receive the correct information about various 
mutations due to a lack of knowledge of these professionals. 
4.1.3 Barriers and facilitators for implementation of this guideline 
During the stakeholders meeting on February 23rd 2015, the potential 
barriers and facilitators related to the use of this guideline were discussed. 
The new billing codes for genetic tests (article 33) and the agreement on 
genetic testing consultation are in line with the recommendations in this 
guideline, and will facilitate its implementation. 
The development of patient leaflets and information based on the present 
guideline will provide the means to clearly inform patients and their relatives 
about the indications for genetic testing and its consequences. These 
leaflets can be developed in collaboration with patients’ representatives and 
organisations, such as the Flemish Cancer League, Fondation contre le 
cancer, Zelfhulpgroep NET & MEN kanker and VHL Family Alliance 
Belgium. 
An important barrier is that these recommendations concern rare diseases 
for which the care is not necessarily centralised. Furthermore, the evidence 
is mainly of low to very low quality, and clinicians may be reluctant to 
implement recommendations based on such evidence. 
4.1.4 Actors of the implementation of this guideline 
Clinical guidelines provide a tool for physicians to consult at different stages 
of the patient management pathway: screening, diagnosis, treatment and 
follow-up. They are developed according to standardised principles, based 
on scientific information regularly updated from the international literature. 
KCE formulates recommendations addressed to specific audiences 
(clinicians, decision-makers, sickness funds, NIHDI, professional 
organizations, hospital managers,...).  KCE is not involved in the decision 
making process itself, nor in the execution of the decisions.  
The implementation of this guideline will be facilitated by tools developed 
the College of Human Genetics and the College of Oncology. In addition, 
the content of this guideline is intended to be disseminated to caregiver 
groups by scientific and professional organisations using diverse channels 
such as websites and sessions of continuing education. 
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4.2 Monitoring the quality of care  
This guideline should be considered as a starting point to develop quality 
improvement programs that targets all caregivers concerned.  
It can be used as a tool to support health policies to improve the quality of 
care, e.g. through the support of actions to increase caregivers’ awareness 
and to improve their practice, or through the development (or revision) of 
sets of process and outcome quality indicators.  
4.3 Guideline update 
In view of the rapidly evolving evidence due to the dynamic nature of this 
field, the clinical introduction of the routine analysis of a broad panel of 
germline DNA tests in at risk subjects will be monitored by the authors of 
this report. This guideline should be updated when sufficient new evidence 
is available. If, in the meantime, important new evidence would become 
available, this should be taken into consideration in the medical decision 
making.   
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